,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,248,1,1,,75216,4763,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
1,248,1,1,,419552,4763,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
2,423,1,1,,11109645,4763,Active,,,,,NINDS Anticonvulsant Data (Qualitative),Other,,
3,424,2,1,,11109645,4763,Active,,,,,NINDS Anticonvulsant Data (Quantitative),Other,,
4,880,2,1,,29215458,4763,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
5,880,2,1,,29215458,4763,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
6,881,2,2,,29215458,4763,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
7,894,2,1,,29215458,4763,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
8,1030,2,1,,29215458,4763,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
9,1188,1,2,,48414897,4763,Active,,,,,DSSTox (EPAFHM) EPA Fathead Minnow Acute Toxicity,Other,,
10,1189,1,5,,48414299,4763,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
11,1191,1,3,,48414299,4763,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Hamster Bioassay Results,Other,,
12,1194,1,3,,48414299,4763,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
13,1195,1,2,,48416415,4763,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
14,1199,1,3,,48414299,4763,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
15,1205,1,4,,48414299,4763,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
16,1208,1,3,,48414299,4763,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
17,1379,1,2,,29215458,4763,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
18,1452,1,1,,29215458,4763,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
19,1457,1,1,,29215458,4763,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
20,1460,1,3,,29215458,4763,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
21,1463,1,1,,29215458,4763,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
22,1467,1,3,,29215458,4763,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
23,1468,1,1,,29215458,4763,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
24,1469,1,1,,29215458,4763,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
25,1471,2,1,,29215458,4763,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
26,1476,2,1,,29215458,4763,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
27,1477,1,1,,29215458,4763,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
28,1478,2,1,,29215458,4763,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
29,1479,1,2,,29215458,4763,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
30,1487,1,1,,29215458,4763,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
31,1490,2,1,,29215458,4763,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
32,1580,1,1,,8150142,4763,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
33,1581,1,1,,8150142,4763,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
34,1582,1,1,,8150142,4763,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
35,1583,1,1,,8150142,4763,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
36,1584,1,1,,8150142,4763,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
37,1585,1,1,,8150142,4763,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
38,1586,1,1,,8150142,4763,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
39,1587,1,1,,8150142,4763,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
40,1588,1,1,,8150142,4763,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
41,1589,1,1,,8150142,4763,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
42,1590,1,1,,8150142,4763,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
43,1593,1,1,,8150142,4763,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
44,1594,1,1,,8150142,4763,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
45,1595,1,1,,8150142,4763,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
46,1596,1,1,,8150142,4763,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
47,1597,1,1,,8150142,4763,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
48,1598,1,1,,8150142,4763,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
49,1599,1,1,,8150142,4763,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
50,1600,1,1,,8150142,4763,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
51,1601,1,1,,8150142,4763,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
52,1602,1,1,,8150142,4763,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
53,1603,1,1,,8150142,4763,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
54,1604,1,1,,8150142,4763,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
55,1605,1,1,,8150142,4763,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
56,1606,1,1,,8150142,4763,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
57,1607,1,1,,8150142,4763,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
58,1608,1,1,,8150142,4763,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
59,1609,1,1,,8150142,4763,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
60,1610,1,1,,8150142,4763,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
61,1612,1,1,,8150142,4763,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
62,1613,1,1,,8150142,4763,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
63,1614,1,1,,8150142,4763,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
64,1616,1,1,,8150142,4763,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
65,1688,1,1,,29215458,4763,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
66,1766,1,1,,29215458,4763,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
67,1766,1,1,,29215458,4763,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
68,1768,1,1,,29215458,4763,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
69,1768,1,1,,29215458,4763,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
70,1865,1,1,,29215458,4763,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
71,1948,1,1,,29215458,4763,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
72,1996,2,2,,51087546,4763,Active,,,,,Aqueous Solubility from MLSMR Stock Solutions,Other,,
73,2016,1,3,,51087546,4763,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
74,2023,1,3,,51087546,4763,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
75,2025,1,3,,51087546,4763,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
76,2029,1,3,,51087546,4763,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
77,2052,2,1,,51087546,4763,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
78,2066,1,4,,51087546,4763,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
79,2101,1,1,,29215458,4763,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
80,2107,1,1,,29215458,4763,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
81,2112,1,1,,29215458,4763,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
82,2280,2,3,,51087546,4763,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
83,2314,1,2,,29215458,4763,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
84,2314,1,2,,29215458,4763,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
85,2315,1,2,,29215458,4763,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
86,2315,1,2,,29215458,4763,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
87,2380,1,2,,51087546,4763,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
88,2435,1,2,,51087546,4763,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
89,2445,1,2,,51087546,4763,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
90,2451,1,2,,29215458,4763,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
91,2472,1,2,,29215458,4763,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
92,2517,2,1,,51087546,4763,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
93,2517,2,1,,144205266,4763,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
94,2520,1,4,,51087546,4763,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
95,2521,1,3,,51087546,4763,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
96,2524,1,2,,51087546,4763,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
97,2528,1,2,,29215458,4763,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
98,2540,1,2,,51087546,4763,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
99,2544,1,2,,51087546,4763,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
100,2546,1,1,,29215458,4763,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
101,2549,1,1,,29215458,4763,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
102,2551,1,1,,29215458,4763,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
103,2557,1,3,,51087546,4763,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
104,2599,1,2,,51087546,4763,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
105,2606,1,2,,51087546,4763,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
106,2662,2,1,,29215458,4763,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
107,2690,1,2,,51087546,4763,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
108,2751,2,2,,51087546,4763,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
109,2796,1,4,,51087546,4763,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
110,2797,1,2,,51087546,4763,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
111,2805,2,2,,51087546,4763,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
112,2806,2,2,,51087546,4763,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
113,2825,1,2,,51087546,4763,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
114,19262,5,1,,103165722,4763,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
115,22293,4,4,,103165722,4763,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
116,22948,3,4,,103165722,4763,Unspecified,,,,,Neurologic toxicity determined using rotarod test in mice,Other,8230125.0,
117,22950,3,3,,103165722,4763,Unspecified,,,,,Time of peak effect (TPE) for activity,Other,1992141.0,
118,22951,3,3,,103165722,4763,Unspecified,,,,,Time of peak effect (TPE) for toxicity,Other,1992141.0,
119,23251,3,3,,103165722,4763,Unspecified,,,,,Partition coefficient (logP),Other,3599019.0,
120,23252,3,3,,103165722,4763,Unspecified,,,,,Partition coefficient (logP) (benzene),Other,3599019.0,
121,23253,3,3,,103165722,4763,Unspecified,,,,,Partition coefficient (logP) (carbon tetrachloride),Other,3599019.0,
122,23254,3,3,,103165722,4763,Unspecified,,,,,Partition coefficient (logP) (chloroform),Other,3599019.0,
123,23255,3,3,,103165722,4763,Unspecified,,,,,Partition coefficient (logP) (ether),Other,3599019.0,
124,23256,3,3,,103165722,4763,Unspecified,,,,,Partition coefficient (logP) (hexane),Other,3599019.0,
125,23672,3,3,,103165722,4763,Unspecified,,,,,Partition coefficient (logP),Other,7381857.0,
126,24211,3,3,,103165722,4763,Unspecified,,,,,Compound is evaluated for ionization constant log k,Other,6864729.0,
127,25870,3,3,,103165722,4763,Unspecified,,,,,Tested for the dissociation constant of the compound,Other,7381857.0,
128,26304,4,4,,103165722,4763,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
129,26320,3,3,,103165722,4763,Unspecified,,,,,pKa value is evaluated,Other,6864729.0,
130,29307,3,4,,103165722,4763,Unspecified,,,,,Neurotoxic dose (TD50) in mice using the rotarod test,Other,1875341.0,
131,29359,3,3,,103165722,4763,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
132,29811,4,3,,103165722,4763,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
133,38914,3,3,,103165722,4763,Unspecified,,,,,Negative log of molar concentration (-log ED50) required to reduce cell division by 50% in Arbacia egg,Other,6864729.0,
134,40039,3,3,,103165722,4763,Unspecified,,,,,Antagonist activity to generalized seizures Photically induced seizures in senegalese Papio papio baboons,Other,3950916.0,
135,47015,3,3,,103165722,4763,Unspecified,,,,,Dose elevating electroshock induced seizure by 20% in CF1 mice after ip administration.,Other,1495012.0,
136,47018,6,2,,103165722,4763,Unspecified,,,,,Dose protecting 50% of the mice from tonic hind limb extension at the time of peak convulsant effect after ip administration.,Other,1495012.0,
137,47022,3,4,,103165722,4763,Unspecified,,,,,Dose showing neurotoxicity in 50% of the at the time of peak neurotoxic effect in CF1 MICE after ip administration.,Other,1495012.0,
138,47024,5,1,,103165722,4763,Unspecified,,,,,Time of peak anticonvulsant effect in CF1 MICE after ip administration.,Other,1495012.0,
139,47027,5,1,,103165722,4763,Unspecified,,,,,Time of peak neurotoxic effect in CF1 MICE after ip administration.,Other,1495012.0,
140,50620,6,2,,103165722,4763,Unspecified,,,,,Compound was evaluated for effective dose by subcutaneous pentylenetetrazole test after intraperitoneal administration of the compound.,Other,1992141.0,
141,51428,3,3,,103165722,4763,Unspecified,,,,,Compound was evaluated for toxic dose at peak neurologic deficit after intraperitoneal administration of the compound.,Other,1992141.0,
142,53026,6,2,,103165722,4763,Unspecified,,,,,Compound was evaluated for effective dose by maximal electroshock test after intraperitoneal administration of the compound.,Other,1992141.0,
143,71428,9,2,,103165722,4763,Unspecified,,,10.0,IC50,Inhibition of [3H]BTX binding to guinea pig voltage-dependent sodium channel,Confirmatory,3016269.0,
144,76484,3,4,,103165722,4763,Unspecified,,,,,Binding to guinea pig atrial homogenate,Other,7381857.0,
145,91480,3,8,,103165722,4763,Unspecified,,,,,Ability to bind to human serum albumin (HSA),Other,7381857.0,
146,109894,6,1,,103165722,4763,Unspecified,,,,,Antiepileptic (anticonvulsant) activity in mice through maximal electroshock seizure (MES) assay,Other,3016269.0,
147,110223,6,2,,103165722,4763,Unspecified,,,,,Ability to prevent the tonic extensor component induced by 106.25 mg/kg sc of pentylenetetrazole,Other,8035421.0,
148,112157,6,2,,103165722,4763,Unspecified,,,,,Effective dose required to prevent tonic extension of the hind limbs in mice in the maximal electroshock seizures (MES) test when administered intraperitoneally,Other,7799408.0,
149,112174,6,2,,103165722,4763,Unspecified,,,,,Effective dose was evaluated for its anticonvulsant activity against subcutaneous induced metrazole convulsions in mice; 5.87-15.95,Other,4032429.0,
150,112301,5,3,,103165722,4763,Unspecified,,,,,"Compound was tested for anticonvulsant activity in male mice by pentylenetetrazole (80 mg/kg, sc) induced seizure test.",Other,,
151,112303,5,3,,103165722,4763,Unspecified,,,,,Compound was tested for anticonvulsant activity in male mice using maximal electric shock seizure test.,Other,,
152,112397,6,2,,103165722,4763,Unspecified,,,,,Yohimbine induced seizures by administrating sc and the compound which do not exhibit at least one clonic seizure within 60 min was recorded,Other,8035421.0,
153,113153,7,2,,103165722,4763,Unspecified,,,,,Concentration required to prevent seizures upon intraperitoneal administration in mice in MES (maximal electroshock seizure) test.,Other,1875341.0,
154,113639,6,2,,103165722,4763,Unspecified,,,,,ED50 was evaluated from MES test in mice by delivering intraperitoneally and the value was determined at peak time effect or peak neurologic effect.,Other,2061925.0,
155,113640,6,2,,103165722,4763,Unspecified,,,,,ED50 was evaluated from scMET test in mice by delivering intraperitoneally and the value was determined at peak time effect or peak neurologic effect.,Other,2061925.0,
156,113699,6,2,,103165722,4763,Unspecified,,,,,Inhibition of seizures induced in mice by a convulsant dose of bicuculline through ip administration,Other,8691481.0,
157,113702,6,2,,103165722,4763,Unspecified,,,,,Inhibition of picrotoxin-induced seizures in mice by ip administration,Other,8691481.0,
158,113706,6,2,,103165722,4763,Unspecified,,,,,Inhibition of seizures induced in mice by a convulsant dose of strychnine through ip administration,Other,8691481.0,
159,113777,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity expressed as dose at which 50% of the mice were protected from clonic seizures induced by pentylenetetrazole (85 mg/Kg),Other,9016327.0,
160,113779,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity expressed as dose at which 50% of the mice were protected from tonic hindlimb seizures induced by maximal electroshock (MES),Other,9016327.0,
161,113782,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in mice against pentylenetetrazole (PTZ) induced clonic seizures,Other,8627613.0,
162,113858,7,2,,103165722,4763,Unspecified,,,,,Effective dose against maximal electroshock seizure in mice after intraperitoneal administration,Other,8627614.0,
163,113901,6,2,,103165722,4763,Unspecified,,,,,Median Effective dose was evaluated by Maximal electroshock seizure (MES) test in mice by oral administration,Other,8691481.0,
164,113903,6,2,,103165722,4763,Unspecified,,,,,Median Effective dose was evaluated by Subcutaneous pentylenetetrazole seizure test in mice by oral administration,Other,8691481.0,
165,113905,6,2,,103165722,4763,Unspecified,,,,,Median effective dose was evaluated by Maximal electroshock seizure test through intraperitoneal administration,Other,8691481.0,
166,113907,6,2,,103165722,4763,Unspecified,,,,,Median effective dose was evaluated by subcutaneous pentylenetetrazole seizure test through intraperitoneal administration,Other,8691481.0,
167,113971,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity was determined by maximum-induced convulsions electroshock seizure test (Phase II Pharmacological Evaluation),Other,3820228.0,
168,113973,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity was determined by maximum-induced convulsions electroshock seizure test (Phase IV Pharmacological Evaluation),Other,3820228.0,
169,113974,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity was determined by maximum-induced convulsions electroshock seizure test (Phase V Pharmacological Evaluation),Other,3820228.0,
170,113977,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity was determined by subcutaneous Metrazol-induced convulsions seizure test (Phase II Pharmacological Evaluation),Other,3820228.0,
171,113979,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity was determined by subcutaneous Metrazol-induced convulsions seizure test (Phase IV Pharmacological Evaluation),Other,3820228.0,
172,113981,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity was determined by subcutaneous Metrazol-induced convulsions seizure test (Phase V Pharmacological Evaluation),Other,3820228.0,
173,113995,6,2,,103165722,4763,Unspecified,,,,,Effective dose evaluated against maximal electric seizures (MES) or convulsions in mice; 14.99-25.52,Other,4032429.0,
174,114126,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in mice using the maximal electroshock seizure test.,Other,8035421.0,
175,114137,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity against bicuculline induced seizures in mice,Other,8035421.0,
176,114381,6,2,,103165722,4763,Unspecified,,,,,Tested for NMDLA induced seizures and protection against full generalized tonic seizures was recorded,Other,8035421.0,
177,114420,3,3,,103165722,4763,Unspecified,,,,,Median hypnotic dose was evaluated by loss of righting reflex,Other,8691481.0,
178,114483,6,2,,103165722,4763,Unspecified,,,,,Compound for anticonvulsant activity against maximal electroshock (MES) induced seizures in mice after administration,Other,3735320.0,
179,114485,6,2,,103165722,4763,Unspecified,,,,,Compound for anticonvulsant activity against subcutaneous pentylenetetrazole-induced convulsions in mice after administration,Other,3735320.0,
180,114576,6,2,,103165722,4763,Unspecified,,,,,Tested for the abolition of the hand leg tonic extensor component of the seizure induced by a 0.96 mg/kg sc injection of strychnine; Percentage of protection at 100 mg/kg per os.,Other,8035421.0,
181,114622,6,2,,103165722,4763,Unspecified,,,,,Evaluated for Bicuculline-induced lethality (anticonvulsant activity) when administered orally in mice.,Other,3950916.0,
182,114624,6,2,,103165722,4763,Unspecified,,,,,Compound was evaluated for Bicuculline-induced seizures (anticonvulsant activity)when administered orally in mice,Other,3950916.0,
183,114634,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in Maximal electroshock (MES) when administered orally in mice,Other,3950916.0,
184,114801,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in Clonic seizures when administered orally in mice,Other,3950916.0,
185,114802,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in tonic seizures when administered orally in mice,Other,3950916.0,
186,114817,6,2,,103165722,4763,Unspecified,,,,,Sedative properties by the rotarod test,Other,3950916.0,
187,117223,6,2,,103165722,4763,Unspecified,,,,,Median lethal dose was evaluated by mortality after 24 hr through ip injection administration,Other,8691481.0,
188,121847,3,3,,103165722,4763,Unspecified,,,,,Central nervous system toxicity was performed by determining the median toxic dose in the rotarod test,Other,8035421.0,
189,121848,3,4,,103165722,4763,Unspecified,,,,,Compound for toxicity by rotarod assay method in mice after administration,Other,3735320.0,
190,121850,4,4,,103165722,4763,Unspecified,,,,,Compound was tested for rotarod test in mice and TD50 value at which 50% of trained animals fall off rotarod,Other,3783590.0,
191,121851,3,4,,103165722,4763,Unspecified,,,,,Compound was tested for rotarod test in mice and TD50 value at which 50% of trained animals fall off rotarod was reported,Other,3783590.0,
192,121858,3,4,,103165722,4763,Unspecified,,,,,Median Effective dose was evaluated by Neurologic toxicity (rotarod test) in mice by oral administration,Other,8691481.0,
193,121859,3,4,,103165722,4763,Unspecified,,,,,Median neurologically impairing dose was determined in mice using the rotarod test,Other,7799408.0,
194,121861,3,3,,103165722,4763,Unspecified,,,,,Median toxic dose was evaluated by Maximal electroshock seizure test and subcutaneous pentylenetetrazole seizure test through intraperitoneal administration,Other,8691481.0,
195,121863,3,4,,103165722,4763,Unspecified,,,,,Neurologic toxicity activity was determined by rotarod toxicity test (Phase II Pharmacological Evaluation),Other,3820228.0,
196,121864,3,4,,103165722,4763,Unspecified,,,,,Neurologic toxicity activity was determined by rotarod toxicity test (Phase IV Pharmacological Evaluation),Other,3820228.0,
197,121865,3,4,,103165722,4763,Unspecified,,,,,Neurologic toxicity activity was determined by rotarod toxicity test (Phase V Pharmacological Evaluation),Other,3820228.0,
198,121999,3,4,,103165722,4763,Unspecified,,,,,Neurotoxic toxicity in mice was evaluated by rotarod test after intraperitoneal administration,Other,8627614.0,
199,122004,3,4,,103165722,4763,Unspecified,,,,,Neurotoxicity was determined from the rotarod ataxia test for the compound by the intraperitoneal administration.,Other,2061925.0,
200,122017,3,4,,103165722,4763,Unspecified,,,,,Toxic dose was determined by the rotarod test in mice; 62.84-72.89,Other,4032429.0,
201,122341,3,3,,103165722,4763,Unspecified,,,,,Time to peak activity was evaluated by Maximal electroshock seizure test in hours,Other,8691481.0,
202,122455,3,3,,103165722,4763,Unspecified,,,,,Time to peak effect in mice was evaluated by Maximal electroshock seizure (MES) test in hours by oral administration,Other,8691481.0,
203,122456,3,4,,103165722,4763,Unspecified,,,,,Time to peak effect in mice was evaluated by Neurologic toxicity (rotarod test) in hours by oral administration,Other,8691481.0,
204,122458,3,3,,103165722,4763,Unspecified,,,,,Time to peak effect in mice was evaluated by Subcutaneous pentylenetetrazole seizure test in hours by oral administration,Other,8691481.0,
205,122459,3,3,,103165722,4763,Unspecified,,,,,Time to peak toxicity was evaluated by Maximal electroshock seizure test in hours,Other,8691481.0,
206,123952,3,3,,103165722,4763,Unspecified,,,,,Locomotor activity in maximal electroshock seizure+ indicates increase at 100 mg/kg,Other,8035421.0,
207,127821,5,1,,103165722,4763,Unspecified,,,,,The effective dose of compound was tested against maximal electroshock induced seizures after intraperitoneal administration.,Other,2308142.0,
208,127822,5,1,,103165722,4763,Unspecified,,,,,The effective dose of compound was tested against subcutaneous administered Metrazol induced seizures after intraperitoneal administration.,Other,2308142.0,
209,127859,6,2,,103165722,4763,Unspecified,,,,,"Compound was evaluated in vivo for reserpine hypothermia after oral administration in mouse. Minimum active dose was reported, with the percent reversal at 10 mg/kg in parenthesis.",Other,6716399.0,
210,128037,6,2,,103165722,4763,Unspecified,,,,,Compound was tested for anticonvulsant activity against bicuculline-induced clonic seizures in mice at 2.7 mg/kg sc,Other,1681105.0,
211,128038,6,2,,103165722,4763,Unspecified,,,,,"Compound was tested for anticonvulsant activity against maximal electroshock-induced clonic seizures in mice at 50mA, 200 ms",Other,1681105.0,
212,128040,6,2,,103165722,4763,Unspecified,,,,,Compound was tested for anticonvulsant activity against pentylenetetrazole-induced clonic seizures in mice at 80 mg/kg sc,Other,1681105.0,
213,128044,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity against picrotoxin-induced clonic seizures in mice at 3.2 mg/kg sc,Other,1681105.0,
214,128694,5,1,,103165722,4763,Unspecified,,,,,Time of peak effect activity against maximal electroshock induced seizures,Other,2308142.0,
215,129015,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity by using bicuculline test in mice,Other,2724304.0,
216,129017,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity by using maximal electroshock seizure test in mice,Other,2724304.0,
217,129018,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity by using subcutaneous pentylenetetrazole (Metrazol) seizure threshold test in mice,Other,2724304.0,
218,129171,6,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in mice, measured by subcutaneous pentylenetetrazole seizure (scMet) test.",Other,3336019.0,
219,129174,6,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in mice, measured by maximal electroshock seizure (MES) test.",Other,3336019.0,
220,129640,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in mouse maximal electroshock assay following i.p. administration.,Other,7205879.0,
221,129806,6,2,,103165722,4763,Unspecified,,,,,Compound was evaluated for anticonvulsant activity by maximal electroshock assay(MES) in mice after po administration.,Other,7205879.0,
222,129971,6,2,,103165722,4763,Unspecified,,,,,Compound was evaluated for inhibition of hind limb tonus (anticonvulsant activity ) in mouse against maximal electroshock seizures (MES) after peroral administration,Other,3783590.0,
223,129972,6,2,,103165722,4763,Unspecified,,,,,Compound was evaluated for inhibition of hind limb tonus (anticonvulsant activity ) in mouse maximal electroshock seizures (MES) at time of peak effect after ip administration,Other,3783590.0,
224,129973,6,2,,103165722,4763,Unspecified,,,,,Compound was evaluated for inhibition of hind limb tonus (anticonvulsant activity ) in mouse maximal metrazole seizures (MMS) after peroral administration,Other,3783590.0,
225,130126,6,2,,103165722,4763,Unspecified,,,,,Compound was evaluated for maximal electroshock antagonism (MES) against mice (values in parentheses indicates 95% confidence limits),Other,6716399.0,
226,130888,6,2,,103165722,4763,Unspecified,,,,,Inhibition of hind limb tonus was tested at time of peak effect by maximal electroshock test (MES) in mouse on intraperitoneal administration of compound,Other,3783589.0,
227,130889,6,2,,103165722,4763,Unspecified,,,,,Inhibition of hind limb tonus was tested at time of peak effect by maximal metrazole seizure (MMS) test administered intraperitoneally in mouse,Other,3783589.0,
228,130890,6,2,,103165722,4763,Unspecified,,,,,Inhibition of hind limb tonus was tested by maximal electroshock test (MES) in mouse after 1 hr of peroral administration of compound,Other,3783589.0,
229,130891,6,2,,103165722,4763,Unspecified,,,,,Inhibition of hind limb tonus was tested by maximal metrazole seizure (MMS) test in mouse after 1 hr of peroral administration,Other,3783589.0,
230,131201,6,2,,103165722,4763,Unspecified,,,,,Concentration required to inhibit seizures was determined in MES test after (ip) administration in mice,Other,2308141.0,
231,131217,6,2,,103165722,4763,Unspecified,,,,,Maximal electroshock seizures was determined for the inhibition of hind limb tonus in mouse by 1 hr after po dose,Other,3572984.0,
232,131218,6,2,,103165722,4763,Unspecified,,,,,Maximal metrazole seizures was determined for the inhibition of hind limb tonus in mouse 1 hr after po dosing,Other,3572984.0,
233,131349,5,3,,103165722,4763,Unspecified,,,,,Dose required to produce a 50% elevation in seizure threshold after oral administration,Other,,
234,131587,6,2,,103165722,4763,Unspecified,,,,,Subcutaneous metrazole (scMet) test was conducted and median effective dose was determined at the time of peak anticonvulsant and sedative effect.,Other,2296016.0,
235,131776,6,2,,103165722,4763,Unspecified,,,,,Tested for inhibition of 3-mercaptopropanoic acid induced seizures in mice.,Other,2170646.0,
236,131910,6,2,,103165722,4763,Unspecified,,,,,Tested for inhibition of bicuculline induced seizures in mice.,Other,2170646.0,
237,131913,6,2,,103165722,4763,Unspecified,,,,,Tested for inhibition of maximal electroshock -induced seizures in mice.,Other,2170646.0,
238,131925,6,2,,103165722,4763,Unspecified,,,,,Tested for inhibition of pentylenetetrazole induced seizures in mice.,Other,2170646.0,
239,131927,6,2,,103165722,4763,Unspecified,,,,,Tested for inhibition of quinoline-induced seizures in mice.,Other,2170646.0,
240,131932,6,2,,103165722,4763,Unspecified,,,,,Tested for inhibition of strychnine-induced seizures in mice.,Other,2170646.0,
241,131996,3,3,,103165722,4763,Unspecified,,,,,Median hypnotic dose by loss of righting reflex.,Other,2308142.0,
242,132226,7,2,,103165722,4763,Unspecified,,,,,Effective dose required for maximal electroshock (MES)-induced seizures in mice.,Other,8230125.0,
243,132405,6,2,,103165722,4763,Unspecified,,,,,Evaluated against Maximal electroshock seizure test in mice after ip administration,Other,11311072.0,
244,132424,6,2,,103165722,4763,Unspecified,,,,,Evaluation of inhibitory activity aagainst MES induced convulsions in mice,Other,6737420.0,
245,132428,6,2,,103165722,4763,Unspecified,,,,,Evaluation of inhibitory activity against scMet induced convulsions in mice,Other,6737420.0,
246,132470,6,2,,103165722,4763,Unspecified,,,,,The compound was tested for anticonvulsant activity against (subcutaneous administered) Metrazol induced seizures after intraperitoneal administration,Other,2308142.0,
247,132472,6,2,,103165722,4763,Unspecified,,,,,The compound was tested for anticonvulsant activity against (subcutaneous administered) bicuculline induced seizures after intraperitoneal administration,Other,2308142.0,
248,132474,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity against subcutaneous picrotoxin induced seizures after intraperitoneal administration,Other,2308142.0,
249,132475,6,2,,103165722,4763,Unspecified,,,,,The compound was tested for anticonvulsant activity against (subcutaneous administered) strychnine induced seizures after intraperitoneal administration,Other,2308142.0,
250,132636,6,2,,103165722,4763,Unspecified,,,,,The compound was tested to inhibit 50% of induced maximal electroshock seizure in mice on ip administration,Other,9544213.0,
251,132638,6,2,,103165722,4763,Unspecified,,,,,The compound was tested to inhibit 50% of induced subcutaneous pentylenetetrazole seizure in mice on ip administration,Other,9544213.0,
252,132649,6,2,,103165722,4763,Unspecified,,,,,The effective dose of compound was tested against maximal electroshock induced seizures after oral administration in mice.,Other,2308142.0,
253,132653,6,2,,103165722,4763,Unspecified,,,,,The effective dose of compound was tested against subcutaneous administered Metrazol induced seizures in mice,Other,2308142.0,
254,134302,3,3,,103165722,4763,Unspecified,,,,,Protective index between TD50/MES ED50 when administered intraperitoneally to mice,Other,8627614.0,
255,134323,4,3,,103165722,4763,Unspecified,,,,,Protective index value is the ratio between TD50 and ED50 values.,Other,9544213.0,
256,134421,6,2,,103165722,4763,Unspecified,,,,,Compound was evaluated for lethal dose in mouse in groups of ten (values in parentheses indicates 95% confidence limits),Other,6716399.0,
257,134730,6,2,,103165722,4763,Unspecified,,,,,Lethal dose was measured in mice after ip administration.,Other,7205879.0,
258,134733,6,2,,103165722,4763,Unspecified,,,,,Median lethal dose was measured after 24 hr.,Other,2308142.0,
259,134938,3,3,,103165722,4763,Active,,,,,Mouse behavior activity was determined; D = Depressant,Other,6716399.0,
260,135109,3,3,,103165722,4763,Unspecified,,,,,Dose causing a neurological deficit in 50% of mice after ip administration.,Other,7205879.0,
261,135133,3,3,,103165722,4763,Unspecified,,,,,Dose causing a neurological deficit in 50% of mice following p.o. administration.,Other,7205879.0,
262,136085,3,3,,103165722,4763,Unspecified,,,,,The cytotoxicity after intraperitoneal administration,Other,2308142.0,
263,136086,3,3,,103165722,4763,Unspecified,,,,,The cytotoxicity after intraperitoneal administration in mice.,Other,2308142.0,
264,136087,3,4,,103165722,4763,Unspecified,,,,,Anticonvulsant activity by using rotarod toxicity test in mice,Other,2724304.0,
265,136102,3,4,,103165722,4763,Unspecified,,,,,Evaluated against neurological toxicity determined from the rotarod test in mice after ip administration,Other,11311072.0,
266,136106,3,4,,103165722,4763,Unspecified,,,,,Evaluation of neurologic deficit by rotarod procedure in mice,Other,6737420.0,
267,136258,3,4,,103165722,4763,Unspecified,,,,,Neurological deficit in mouse measured by rotarod test,Other,3336019.0,
268,136259,3,3,,103165722,4763,Unspecified,,,,,Neurological toxicity was determined using horizontal screen test in mice after intraperitoneal administration,Other,2308141.0,
269,136262,3,4,,103165722,4763,Unspecified,,,,,Neurotoxicity against mice in rotarod test,Other,1681105.0,
270,136273,3,4,,103165722,4763,Unspecified,,,,,Tested for the neurotoxicity in mouse rotarod test was reported 1 hr after po dosing,Other,3572984.0,
271,136276,3,3,,103165722,4763,Unspecified,,,,,The compound was determined for the dose (mg/kg) by rotarod test at the time of peak neurotoxic effect in mice on ip administration,Other,9544213.0,
272,139244,3,3,,103165722,4763,Unspecified,,,,,Righting ability was determined in mice before rapid rolling (aroused),Other,6716399.0,
273,139245,3,3,,103165722,4763,Unspecified,,,,,Righting ability was determined in mice before rapid rolling (unaroused),Other,6716399.0,
274,139328,3,3,,103165722,4763,Unspecified,,,,,Time of peak effect was determined for activity in MES,Other,2308142.0,
275,139329,3,3,,103165722,4763,Unspecified,,,,,Time of peak effect was determined for toxicity,Other,2308142.0,
276,139949,3,3,,103165722,4763,Unspecified,,,,,Compound was evaluated for inhibition of hind limb tonus (anticonvulsant activity ) in mouse,Other,3783590.0,
277,140326,5,1,,103165722,4763,Unspecified,,,,,Time of peak effect toxicity against maximal electroshock induced seizures,Other,2308142.0,
278,167610,3,3,,103165722,4763,Unspecified,,,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),Other,6864729.0,
279,168456,3,3,,103165722,4763,Unspecified,,,,,Compound was tested for its activity in diet-induced Hypercholesterolemic rats at dose 50 mg/kg after peroral administration carnitine acetyl transferase activity(per mg) of protein,Other,3950919.0,
280,168457,3,3,,103165722,4763,Unspecified,,,,,Compound was tested for its activity in diet-induced Hypercholesterolemic rats at dose 50 mg/kg after peroral administration palmitoyl-CoA oxidation activity(per mg) of protein,Other,3950919.0,
281,169097,3,3,,103165722,4763,Unspecified,,,,,Negative log of molar concentration (-log C) required to produce 50% inhibition of oxygen (oxygen uptake) on rat brain respiration in vitro,Other,6864729.0,
282,170471,3,3,,103165722,4763,Unspecified,,,,,Compound was tested for Hepatic peroxisomal proliferation effect in male rats treated for 7 days at dose 50 mg/kg protein,Other,3950919.0,
283,170943,3,3,,103165722,4763,Unspecified,,,,,Compound was tested for Hepatic peroxisomal proliferation effect in male rats treated for 7 days at dose 50 mg/kg concentration of hepatic proteins(mg/g) in liver,Other,3950919.0,
284,176271,6,2,,103165722,4763,Unspecified,,,,,Maximal electroshock seizures determined for the inhibition of hind limb tonus in rat 1 hr after po dosing,Other,3572984.0,
285,176277,6,2,,103165722,4763,Unspecified,,,,,Median Effective dose was evaluated by Maximal electroshock seizure (MES) test in Rats by oral administration,Other,8691481.0,
286,176278,6,2,,103165722,4763,Unspecified,,,,,Median Effective dose was evaluated by Subcutaneous pentylenetetrazole seizure test in Rats by oral administration,Other,8691481.0,
287,177082,6,2,,103165722,4763,Unspecified,,,,,Compound was evaluated for inhibition of hind limb tonus (anticonvulsant activity ) in rat maximal electroshock seizures (MES) after peroral administration,Other,3783590.0,
288,177083,6,2,,103165722,4763,Unspecified,,,,,Compound was evaluated for inhibition of hind limb tonus (anticonvulsant activity ) in rat maximal metrazole seizures (MMS) after peroral administration,Other,3783590.0,
289,177914,6,2,,103165722,4763,Unspecified,,,,,Inhibition of hind limb tonus was tested at time of peak effect by maximal electroshock test (MES) in rat on intraperitoneal administration of compound,Other,3783589.0,
290,178048,6,2,,103165722,4763,Unspecified,,,,,Inhibition of hind limb tonus was tested by maximal electroshock test (MES) in rat after 1 hr of peroral administration,Other,3783589.0,
291,178049,6,2,,103165722,4763,Unspecified,,,,,Inhibition of hind limb tonus was tested by maximal electroshock test (MES) in rat after 4 hr of peroral administration,Other,3783589.0,
292,178051,6,2,,103165722,4763,Unspecified,,,,,Inhibition of hind limb tonus was tested by maximal metrazole seizure test after 1 hr of peroral administration of compound,Other,3783589.0,
293,178052,6,2,,103165722,4763,Unspecified,,,,,Inhibition of hind limb tonus was tested by maximal metrazole seizure test after 4 hr of peroral administration,Other,3783589.0,
294,178377,6,2,,103165722,4763,Unspecified,,,,,Effective dose against maximal electroshock seizure in rat after oral administration,Other,8627614.0,
295,180890,6,2,,103165722,4763,Unspecified,,,,,The cytotoxicity after intraperitoneal administration in rat.,Other,2308142.0,
296,180906,6,2,,103165722,4763,Unspecified,,,,,The effective dose of compound was tested against maximal electroshock induced seizures after oral administration in rat.,Other,2308142.0,
297,180907,6,2,,103165722,4763,Unspecified,,,,,The effective dose of compound was tested against subcutaneous administered Metrazol induced seizures in rat.,Other,2308142.0,
298,189456,3,3,,103165722,4763,Unspecified,,,,,Protective index between TD50/MES ED50 when administered orally to rat,Other,8627614.0,
299,189459,3,3,,103165722,4763,Unspecified,,,,,Protective index (TD50/ED50) was determined against MES induced seizure in rat.,Other,8691481.0,
300,189460,3,3,,103165722,4763,Unspecified,,,,,Protective index (TD50/ED50) was determined against scMet induced seizure in rat.,Other,8691481.0,
301,190111,3,4,,103165722,4763,Unspecified,,,,,Effect of compound on mouse motor performance was tested by performing a rotarod test after 1 hr of peroral administration,Other,3783589.0,
302,190112,3,4,,103165722,4763,Unspecified,,,,,Effect of compound on mouse motor performance was tested by rotarod test administered intraperitoneally,Other,3783589.0,
303,190114,3,4,,103165722,4763,Unspecified,,,,,Median Effective dose was evaluated by Neurologic toxicity (rotarod test) in Rats by oral administration,Other,8691481.0,
304,190122,3,4,,103165722,4763,Unspecified,,,,,Neurotoxic toxicity against Rat was evaluated by rotarod test after oral administration,Other,8627614.0,
305,190294,3,3,,103165722,4763,Unspecified,,,,,Time to peak effect in Rats was evaluated by Maximal electroshock seizure (MES) test in hours by oral administration,Other,8691481.0,
306,190295,3,4,,103165722,4763,Unspecified,,,,,Time to peak effect in Rats was evaluated by Neurologic toxicity (rotarod test) in hours by oral administration,Other,8691481.0,
307,190296,3,3,,103165722,4763,Unspecified,,,,,Time to peak effect in Rats was evaluated by Subcutaneous pentylenetetrazole seizure test in hours by oral administration,Other,8691481.0,
308,190465,3,3,,103165722,4763,Unspecified,,,,,Antagonist activity to generalized seizures kindled amygdaloid seizures in rats,Other,3950916.0,
309,205268,4,7,,103165722,4763,Unspecified,,,,,Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM,Other,2579237.0,
310,212187,3,6,,103165722,4763,Unspecified,,,,,"Compound was tested for anticonvulsant activity in male mice by pentylenetetrazole (80 mg/kg, sc) induced seizure test.; Protective index = TD50/ED50",Other,,
311,212189,3,4,,103165722,4763,Unspecified,,,,,Compound was tested for anticonvulsant activity in male mice using maximal electric shock seizure test; Protective index = TD50/ED50,Other,,
312,212210,3,5,,103165722,4763,Unspecified,,,,,Compound was tested for neurotoxic activity in male mice using rotarod test.,Other,,
313,212342,3,4,,103165722,4763,Unspecified,,,,,Neurotoxicity was evaluated by a rotarod test,Other,9016327.0,
314,217794,9,5,,103165722,4763,Active,116447.0,81574.0,2.5,IC50,Inhibition of [3H]BTX-B binding to neurotoxin site 2 of sodium channel of rat cerebral cortex synaptoneurosomes,Confirmatory,7562939.0,
315,217794,9,5,,103165722,4763,Active,116448.0,24766.0,2.5,IC50,Inhibition of [3H]BTX-B binding to neurotoxin site 2 of sodium channel of rat cerebral cortex synaptoneurosomes,Confirmatory,7562939.0,
316,217794,9,5,,103165722,4763,Active,116449.0,497770.0,2.5,IC50,Inhibition of [3H]BTX-B binding to neurotoxin site 2 of sodium channel of rat cerebral cortex synaptoneurosomes,Confirmatory,7562939.0,
317,221080,4,4,,103165722,4763,Unspecified,,,,,Neurologic toxicity using rotarod test in mice after intraperitoneal administration,Other,12361404.0,
318,221084,3,3,,103165722,4763,Unspecified,,,,,Therapeutic dosage was measured by ip administration in mice; 62.8-72.9,Other,8246220.0,
319,221087,5,1,,103165722,4763,Unspecified,,,,,Time of peak effect of activity of compound was measured by both MES and sc Met test in mice,Other,8246220.0,
320,221089,3,3,,103165722,4763,Unspecified,,,,,Time of peak effect of toxicity of compound was measured by both MES and sc Met test in mice,Other,8246220.0,
321,223109,7,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity using MES test in mice after intraperitoneal administration,Other,12361404.0,
322,223724,4,4,,103165722,4763,Unspecified,,,,,Neurologic toxicity using rotarod test in rat after oral administration,Other,12361404.0,
323,224802,3,4,,103165722,4763,Unspecified,,,,,Average seizure score for the rat cornea 0.5 hr after intraperitoneal administration of 0 mg/Kg of compound,Other,1495012.0,
324,224804,3,4,,103165722,4763,Unspecified,,,,,Average seizure score for the rat cornea 0.5 hr after intraperitoneal administration of 15 mg/Kg of compound,Other,1495012.0,
325,224806,3,4,,103165722,4763,Unspecified,,,,,Average seizure score for the rat cornea 0.5 hr after intraperitoneal administration of 20 mg/Kg of compound,Other,1495012.0,
326,224808,3,4,,103165722,4763,Unspecified,,,,,Average seizure score for the rat cornea 0.5 hr after intraperitoneal administration of 25 mg/Kg of compound,Other,1495012.0,
327,224810,3,4,,103165722,4763,Unspecified,,,,,Average seizure score for the rat cornea 0.5 hr after intraperitoneal administration of 30 mg/Kg of compound,Other,1495012.0,
328,225116,7,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity using MES test in rat after oral administration,Other,12361404.0,
329,225154,6,3,,103165722,4763,Unspecified,,,,,Dose reducing the seizure severity in rat cornea 0.5 hr after peroral administration.,Other,1495012.0,
330,225290,6,2,,103165722,4763,Unspecified,,,,,Effective dose was measured in rat by maximal electroshock method by ip administration; 15.0-25.5,Other,8246220.0,
331,225293,6,2,,103165722,4763,Unspecified,,,,,Effective dose was measured in rat by subcutaneous pentylenetetrazole method by ip administration; 5.9-15.9,Other,8246220.0,
332,226511,3,3,,103165722,4763,Unspecified,,,,,Protective Index (PI) determined as the ratio of toxic dose (TD50) and effective dose (ED50 (MES)),Other,9016327.0,
333,226512,3,3,,103165722,4763,Unspecified,,,,,Protective Index (PI) determined as the ratio of toxic dose (TD50) and effective dose (ED50 (PTZ)),Other,9016327.0,
334,226513,3,3,,103165722,4763,Unspecified,,,,,Protective Index was determined using the ratio of TD50/ED50 value,Other,7799408.0,
335,226517,3,3,,103165722,4763,Unspecified,,,,,Protective index (PI) which is defined as the ratio of TD50 to the ED50 (MES).,Other,6737420.0,
336,226518,3,3,,103165722,4763,Unspecified,,,,,Protective index (PI) which is defined as the ratio of TD50 to the ED50 (ScMet).,Other,6737420.0,
337,226520,3,3,,103165722,4763,Unspecified,,,,,Protective index (TD50/ED50),Other,8230125.0,
338,226522,3,3,,103165722,4763,Unspecified,,,,,Protective index (TD50/ED50) value of the compound,Other,11311072.0,
339,226523,3,4,,103165722,4763,Unspecified,,,,,Protective index (rat) was from the ratio of plasma concentration at which side effects occur by plasma concentration at which anticonvulsant activity occur.,Other,3783589.0,
340,226526,3,3,,103165722,4763,Unspecified,,,,,Protective index is the ratio between TD50 and ED50 values,Other,8035421.0,
341,226534,3,3,,103165722,4763,Unspecified,,,,,Protective index as the ratio of TD50 value against MES to that of ED50 value against MES.,Other,4032429.0,
342,226535,3,3,,103165722,4763,Unspecified,,,,,Protective index as the ratio of TD50 value against scMET to that of ED50 value against scMET.,Other,4032429.0,
343,226538,3,3,,103165722,4763,Unspecified,,,,,Protective index as the ratio of TD50 value to that of ED50 value in mice.,Other,12361404.0,
344,226539,3,4,,103165722,4763,Unspecified,,,,,Protective index as the ratio of TD50 value to that of ED50 value in rat.,Other,12361404.0,
345,226540,4,3,,103165722,4763,Unspecified,,,,,Protective index is defined as ND50 (i.p.) divided by MES ED50(i.p.),Other,7205879.0,
346,226541,4,3,,103165722,4763,Unspecified,,,,,Protective index defined as ND50 (p.o.) divided by MES ED50(op),Other,7205879.0,
347,226702,3,3,,103165722,4763,Unspecified,,,,,Protective index was measured as TD50/MES ED50 in mice on ip administration,Other,1495012.0,
348,226706,3,3,,103165722,4763,Unspecified,,,,,Protective index which is the ratio of TD50 to ED50 of against subcutaneous pentylenetetrazole test,Other,1992141.0,
349,226707,3,3,,103165722,4763,Unspecified,,,,,Protective index which is the ratio of TD50 to ED50 of in maximal electroshock test.,Other,1992141.0,
350,226708,3,3,,103165722,4763,Unspecified,,,,,"Protective index, measure of ratio of TD50 and ED50",Other,8627613.0,
351,226942,3,4,,103165722,4763,Unspecified,,,,,Protectivity index is the ratio of TD50 /MES ED50 from Phase-II evaluation,Other,3820228.0,
352,226943,3,4,,103165722,4763,Unspecified,,,,,Protectivity index is the ratio of TD50 /MES ED50 from Phase-IV evaluation,Other,3820228.0,
353,227295,3,3,,103165722,4763,Unspecified,,,,,Intraperitoneal dose (0 mg/Kg) reducing rat corneal kindling 0.5 hr after administration.,Other,1495012.0,
354,227297,3,3,,103165722,4763,Unspecified,,,,,Intraperitoneal dose (15 mg/Kg) reducing rat corneal kindling 0.5 hr after administration.,Other,1495012.0,
355,227299,3,3,,103165722,4763,Unspecified,,,,,Intraperitoneal dose (20 mg/Kg) reducing rat corneal kindling 0.5 hr after administration.,Other,1495012.0,
356,227301,3,3,,103165722,4763,Unspecified,,,,,Intraperitoneal dose (25 mg/Kg) reducing rat corneal kindling 0.5 hr after administration.,Other,1495012.0,
357,227303,3,3,,103165722,4763,Unspecified,,,,,Intraperitoneal dose (30 mg/Kg) reducing rat corneal kindling 0.5 hr after administration.,Other,1495012.0,
358,227699,3,3,,103165722,4763,Unspecified,,,,,Virtual screen for compounds with anticonvulsant activity,Other,12873507.0,
359,230048,3,3,,103165722,4763,Unspecified,,,,,Ratio of LD50/HD50 was determined,Other,2308142.0,
360,231256,3,3,,103165722,4763,Unspecified,,,,,"Protective index (PI), anticonvulsant activity, ratio of TD50/ED50 value in maximal electroconvulsive shock seizure (MES) test",Other,3336019.0,
361,231257,3,3,,103165722,4763,Unspecified,,,,,"Protective index (PI),anticonvulsant activity, ratio of TD50/ED50 value in scMet test",Other,3336019.0,
362,231263,3,3,,103165722,4763,Unspecified,,,,,Protective index was calculated (TD50/ED50) in MES assay in mice after intraperitoneal administration,Other,2308142.0,
363,231424,3,3,,103165722,4763,Unspecified,,,,,Protective index was calculated (TD50/ED50) in MES assay in mice after oral administration,Other,2308142.0,
364,231425,3,3,,103165722,4763,Unspecified,,,,,Protective index was calculated (TD50/ED50) in MES assay in rat after oral administration,Other,2308142.0,
365,231426,3,3,,103165722,4763,Unspecified,,,,,Protective index was calculated (TD50/ED50) in scMET assay in mice after intraperitoneal administration,Other,2308142.0,
366,231427,3,3,,103165722,4763,Unspecified,,,,,Protective index was calculated (TD50/ED50) in scMET assay in mice after oral administration,Other,2308142.0,
367,231428,3,3,,103165722,4763,Unspecified,,,,,Protective index was calculated (TD50/ED50) in scMET assay in rat after oral administration,Other,2308142.0,
368,231880,3,4,,103165722,4763,Unspecified,,,,,Compound was tested for Hepatic peroxisomal proliferation effect in male rats treated for 7 days at dose 50 mg/kg ratio of % liver weight to % body weight,Other,3950919.0,
369,237685,4,3,,103165722,4763,Unspecified,,,,,Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system,Other,15857133.0,
370,240820,9,2,,103165722,4763,Unspecified,,,3000.0,IC50,Inhibitory concentration against IKr potassium channel,Confirmatory,15324906.0,
371,255433,3,4,,103165722,4763,Unspecified,,,,,"Minimum dose required for anticonvulsant activity when given i.p., in mice upon neurotoxicity seizure using rotarod test",Other,16190747.0,
372,255438,3,3,,103165722,4763,Unspecified,,,,,Protective index (TD50/ED50) produced by compound in mouse after MES test,Other,16139502.0,
373,255439,3,3,,103165722,4763,Unspecified,,,,,Protective index (TD50/ED50) produced by compound in mouse after ScMet test,Other,16139502.0,
374,255715,6,2,,103165722,4763,Unspecified,,,,,Neurotoxicity expressed as median toxic dose (TD50) produced after Rotorod ataxia test in mouse by i.p. administration (range 62.8-72.9),Other,16139502.0,
375,255739,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity of compound expressed in terms of median effective dose (ED50) produced after MES test in mouse by i.p. administration (range 21.8-25.5),Other,16139502.0,
376,255742,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity of compound expressed in terms of median effective dose (ED50) produced after ScMet test in mouse by i.p. administration (range 5.8-15.9),Other,16139502.0,
377,256043,3,3,,103165722,4763,Unspecified,,,,,"Mean sleeping time evaluated for CNS study using the pentobarbital-induced narcosis model at a dose of 100 mg/Kg when given i.p., in mice (No. of animals 6)",Other,16190747.0,
378,256406,3,3,,103165722,4763,Unspecified,,,,,"Minimum dose required for anticonvulsant activity when given i.p., in mice upon subcutaneous picrotoxin seizure",Other,16190747.0,
379,266762,6,1,,103165722,4763,Unspecified,,,,,Effective permeability coefficient in 100% IPM membrane,Other,16789751.0,
380,266763,4,1,,103165722,4763,Unspecified,,,,,Membrane retention in 70% silicon-30% IPM membrane,Other,16789751.0,
381,266764,3,3,,103165722,4763,Unspecified,,,,,"Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane",Other,16789751.0,
382,266765,6,1,,103165722,4763,Unspecified,,,,,Effective permeability coefficient in 70% silicon-30% IPM membrane,Other,16789751.0,
383,266766,3,3,,103165722,4763,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,16789751.0,
384,266767,3,3,,103165722,4763,Unspecified,,,,,Membrane retention in 100% silicon membrane,Other,16789751.0,
385,266768,3,3,,103165722,4763,Unspecified,,,,,"Membrane permeability, CA(t)/CD(0) in 100% silicon membrane",Other,16789751.0,
386,266769,3,3,,103165722,4763,Unspecified,,,,,Membrane retention in 100% IPM membrane,Other,16789751.0,
387,266770,3,3,,103165722,4763,Unspecified,,,,,"Membrane permeability, CA(t)/CD(0) in 100% IPM membrane",Other,16789751.0,
388,266771,6,1,,103165722,4763,Unspecified,,,,,Permeability in human skin,Other,16789751.0,
389,270552,6,2,,103165722,4763,Unspecified,,,,,Protection against PTZ-induced convulsions in ip dosed mouse after 0.5 hrs by scPTZ assay,Other,16793262.0,
390,270557,3,3,,103165722,4763,Inactive,,,,,"Protection against electroshock-induced convulsions in mouse up to 300 mg/kg, ip after 0.5 hrs by MES assay",Other,16793262.0,
391,290720,3,3,,103165722,4763,Active,,,,,"Anticonvulsant activity against maximal-electroshock-induced seizure in mouse at 100 mg/kg, ip after 0.5 hrs",Other,17481896.0,
392,290723,3,3,,103165722,4763,Active,,,,,"Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizure in mouse at 30 mg/kg, ip after 0.5 hrs",Other,17481896.0,
393,290725,3,3,,103165722,4763,Active,,,,,"Anticonvulsant activity against subcutaneous picrotoxin-induced seizure in mouse at 30 mg/kg, ip after 0.5 hrs",Other,17481896.0,
394,290729,3,3,,103165722,4763,Active,,,,,"Anticonvulsant activity against subcutaneous picrotoxin-induced seizure in mouse at 100 mg/kg, ip after 4 hrs",Other,17481896.0,
395,290732,3,4,,103165722,4763,Active,,,,,"Acute neurotoxicity in mouse at 100 mg/kg, ip after 0.5 hrs by rotarod test",Other,17481896.0,
396,290733,3,4,,103165722,4763,Active,,,,,"Acute neurotoxicity in mouse at 300 mg/kg, ip after 4 hrs by rotarod test",Other,17481896.0,
397,310931,3,4,,103165722,4763,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17300161.0,
398,310932,3,6,,103165722,4763,Unspecified,,,,,Permeability across human Skin,Other,17300161.0,
399,310933,3,4,,103165722,4763,Unspecified,,,,,Permeability across PAMPA membrane after 7 hrs,Other,17300161.0,
400,311367,3,6,,103165722,4763,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
401,311524,4,3,,103165722,4763,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
402,346025,3,3,,103165722,4763,Unspecified,,,,,Binding affinity to beta cyclodextrin,Other,19056282.0,
403,377482,3,3,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity against CF1 mouse assessed as protection against PTZ-induced convulsions at 0.8 mg/kg, ip for 60 mins",Other,15787439.0,
404,377483,3,3,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity against CF1 mouse assessed as protection against PTZ-induced convulsions at 20 mg/kg, ip for 60 mins",Other,15787439.0,
405,386623,4,8,,103165722,4763,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
406,387784,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino mouse by MES seizure test,Other,18789868.0,
407,387785,3,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed albino mouse by rotarod test,Other,18789868.0,
408,387786,3,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for albino mouse by rotarod test to ED50 for albino mouse by MES seizure test",Other,18789868.0,
409,392051,8,5,,103165722,4763,Unspecified,7531135.0,3757.0,3019.95,IC50,Inhibition of human ERG channel in HEK293 cells by voltage-clamp method,Confirmatory,18262683.0,
410,394934,3,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss albino mouse assessed as minimum drug concentration required for inhibition of maximal electroshock-induced seizure in half or more of mouse after 0.5 hrs by MES test,Other,18396352.0,
411,394935,3,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss albino mouse assessed as minimum drug concentration required for inhibition of maximal electroshock-induced seizure in half or more of mouse after 4 hrs by MES test,Other,18396352.0,
412,394938,3,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss albino mouse assessed as minimum drug concentration required for inhibition of pentylenetetrazole-induced seizures in half or more of mouse after 0.5 hrs by scPTZ test,Other,18396352.0,
413,394939,3,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss albino mouse assessed as minimum drug concentration required for inhibition of pentylenetetrazole-induced seizures in half or more of mouse after 4 hrs by scPTZ test,Other,18396352.0,
414,394945,3,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Swiss albino mouse assessed as minimum drug concentration required for falling off the rotarod by half or more of mouse after 0.5 hrs by rotarod test,Other,18396352.0,
415,394946,3,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Swiss albino mouse assessed as minimum drug concentration required for falling off the rotarod by half or more of mouse after 4 hrs by rotarod test,Other,18396352.0,
416,404304,3,10,,103165722,4763,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
417,408116,3,3,,103165722,4763,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,18467106.0,
418,408118,3,3,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Albino mouse assessed as protection against pentylenetetrazole-induced seizures at 30 mg/kg, ip administered 1 hr before pentylenetetrazole challenge",Other,18467106.0,
419,408121,3,3,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Albino mouse assessed as protection against pentylenetetrazole-induced seizures at 10 mg/kg, ip administered 1 hr before pentylenetetrazole challenge",Other,18467106.0,
420,408122,3,3,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Albino mouse assessed as protection against pentylenetetrazole-induced seizures at 20 mg/kg, ip administered 1 hr before pentylenetetrazole challenge",Other,18467106.0,
421,408123,3,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Albino mouse assessed as protection against pentylenetetrazole-induced seizures administered 1 hr before pentylenetetrazole challenge,Other,18467106.0,
422,409942,11,2,,103165722,4763,Inactive,113978.0,4128.0,,IC50,Inhibition of human recombinant MAOA by fluorimetric method,Confirmatory,18834112.0,
423,425652,7,2,,103165722,4763,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
424,425653,7,2,,103165722,4763,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
425,434955,1,2,,51087546,4763,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
426,434962,1,2,,51087546,4763,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
427,434973,1,3,,51087546,4763,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
428,434989,1,1,,51087546,4763,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
429,435003,1,3,,51087546,4763,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
430,435022,2,2,,51087546,4763,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
431,435030,1,2,,51087546,4763,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
432,435030,1,2,,51087546,4763,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
433,443560,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF1 mouse seizure model assessed as protection against hind limb extension by MES test,Other,20041718.0,
434,443561,3,4,,103165722,4763,Unspecified,,,,,Neurological toxicity in ip dosed albino CF1 mouse assessed as neurological impairment by rotarod test,Other,20041718.0,
435,443562,3,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for ip dosed albino CF1 mouse to ED50 for ip dosed albino CF1 mouse",Other,20041718.0,
436,443563,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat seizure model assessed as protection against hind limb extension by MES test,Other,20041718.0,
437,443564,3,3,,103165722,4763,Unspecified,,,,,Behavioral toxicity in po dosed albino Sprague-Dawley rat,Other,20041718.0,
438,443565,3,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for po dosed albino Sprague-Dawley rat to ED50 for po dosed albino Sprague-Dawley rat",Other,20041718.0,
439,443567,3,3,,103165722,4763,Inactive,,,,,"Anticonvulsant activity against subcutaneous metrazole-induced seizures in albino CF1 mouse at 300 mg/kg, ip after 0.5 hrs",Other,20041718.0,
440,443568,3,3,,103165722,4763,Inactive,,,,,"Anticonvulsant activity against subcutaneous metrazole-induced seizures in albino Sprague-Dawley rat at 300 mg/kg, ip after 0.5 hrs",Other,20041718.0,
441,443569,3,3,,103165722,4763,Inactive,,,,,"Anticonvulsant activity against subcutaneous metrazole-induced seizures in albino CF1 mouse at 300 mg/kg, ip after 4 hrs",Other,20041718.0,
442,443570,3,3,,103165722,4763,Inactive,,,,,"Anticonvulsant activity against subcutaneous metrazole-induced seizures in albino Sprague-Dawley rat at 300 mg/kg, ip after 4 hrs",Other,20041718.0,
443,443571,6,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity against in ip dosed albino Sprague-Dawley rat hippocampal kindled seizure model assessed as decrease in seizures after 0.5 hrs,Other,20041718.0,
444,444050,7,1,,103165722,4763,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
445,444051,6,2,,103165722,4763,Unspecified,,,,,Total clearance in human,Other,20070106.0,
446,444052,6,2,,103165722,4763,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
447,444053,6,2,,103165722,4763,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
448,444054,6,1,,103165722,4763,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
449,444055,3,3,,103165722,4763,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
450,444056,3,3,,103165722,4763,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
451,444057,3,3,,103165722,4763,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
452,444058,6,2,,103165722,4763,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
453,449303,3,3,,103165722,4763,Inactive,,,,,Anticonvulsant activity in ip dosed albino mouse assessed as inhibition of maximal electric shock-induced seizures after 0.5 hrs,Other,19674817.0,
454,449304,3,3,,103165722,4763,Inactive,,,,,Anticonvulsant activity in ip dosed albino mouse assessed as inhibition of maximal electric shock-induced seizures after 4 hrs,Other,19674817.0,
455,449305,3,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizure after 0.5 hrs,Other,19674817.0,
456,449306,3,4,,103165722,4763,Inactive,,,,,Neurotoxicity in ip dosed albino mouse assessed as minimal motor impairment after 0.5 hrs by rotarod test,Other,19674817.0,
457,449307,3,4,,103165722,4763,Inactive,,,,,Neurotoxicity in ip dosed albino mouse assessed as minimal motor impairment after 4 hrs by rotarod test,Other,19674817.0,
458,449311,3,3,,103165722,4763,Inactive,,,,,Anticonvulsant activity in ip dosed albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizure after 4 hrs,Other,19674817.0,
459,449728,1,2,,51087546,4763,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
460,449762,1,2,,51087546,4763,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
461,449763,1,3,,51087546,4763,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
462,463079,1,2,,51087546,4763,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
463,463082,1,1,,51087546,4763,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
464,463104,1,2,,51087546,4763,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
465,463141,1,2,,51087546,4763,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
466,463190,1,2,,51087546,4763,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
467,463195,1,2,,51087546,4763,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
468,463210,1,2,,51087546,4763,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
469,463212,1,1,,51087546,4763,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
470,463254,1,1,,51087546,4763,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
471,467611,3,6,,103165722,4763,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,19586686.0,
472,467612,3,6,,103165722,4763,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
473,467613,5,3,,103165722,4763,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
474,475784,3,4,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed albino mouse assessed as time of peak effect by rotarod test,Other,19795888.0,
475,475785,3,4,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed albino mouse by rotarod test,Other,19795888.0,
476,475789,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino mouse assessed as protection against maximal electroshock-induced seizures,Other,19795888.0,
477,475790,3,4,,103165722,4763,Unspecified,,,,,Anticonvulsant activity against maximal electroshock-induced seizures in ip dosed albino mouse assessed as time of peak effect,Other,19795888.0,
478,475791,3,4,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for ip dosed albino mouse to ED50 for protection against maximal electroshock-induced seizures in ip dosed albino mouse",Other,19795888.0,
479,475792,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures,Other,19795888.0,
480,475793,3,4,,103165722,4763,Unspecified,,,,,Anticonvulsant activity against maximal electroshock-induced seizures in po dosed Sprague-Dawley rat assessed as time of peak effect,Other,19795888.0,
481,475794,3,4,,103165722,4763,Unspecified,,,,,Neurotoxicity in po dosed Sprague-Dawley rat by rotarod test,Other,19795888.0,
482,475795,3,4,,103165722,4763,Unspecified,,,,,Neurotoxicity in po dosed Sprague-Dawley rat assessed as time of peak effect by rotarod test,Other,19795888.0,
483,475797,3,4,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for po dosed Sprague-Dawley rat to ED50 for protection against maximal electroshock-induced seizures in po dosed Sprague-Dawley rat",Other,19795888.0,
484,475798,3,4,,103165722,4763,Inactive,,,,,Anticonvulsant activity in ip dosed albino mouse assessed as protection against subcutaneous metrazole-induced seizures,Other,19795888.0,
485,475799,3,4,,103165722,4763,Inactive,,,,,Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as protection against subcutaneous metrazole-induced seizures,Other,19795888.0,
486,477350,3,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss albino mouse assessed as inhibition of maximum electric shock-induced motor impairment after 0.5 hrs,Other,20116140.0,
487,477351,3,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss albino mouse assessed as inhibition of maximum electric shock-induced motor impairment after 4 hrs,Other,20116140.0,
488,477354,3,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Swiss albino mouse after 0.5 hrs,Other,20116140.0,
489,477355,3,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Swiss albino mouse after 4 hrs,Other,20116140.0,
490,477356,3,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Swiss albino mouse,Other,20116140.0,
491,477357,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss albino mouse assessed as inhibition of maximum electric shock-induced motor impairment,Other,20116140.0,
492,477358,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Swiss albino mouse assessed as inhibition of PTZ-induced motor impairment,Other,20116140.0,
493,477359,3,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in Swiss albino mouse to ED50 for inhibition of maximal electroshock-induced seizures Swiss albino mouse",Other,20116140.0,
494,477728,3,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in Swiss albino mouse to ED50 for inhibition of PTZ-induced motor impairment Swiss albino mouse",Other,20116140.0,
495,480280,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino mouse assessed as inhibition of maximal electroshock-induced seizures after 1 hr,Other,20394379.0,
496,480283,3,3,,103165722,4763,Unspecified,,,,,Toxicity in ip dosed albino mouse after 0.5 hrs by rotarod test,Other,20394379.0,
497,480288,3,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for albino mouse to anticonvulsant ED50 for albino mouse",Other,20394379.0,
498,480294,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed Sprague-Dawley albino rat assessed as inhibition of maximal electroshock-induced seizures after 5 hrs,Other,20394379.0,
499,480299,3,3,,103165722,4763,Unspecified,,,,,Behavioral toxicity in po dosed Sprague-Dawley albino rat after 0.5 hrs,Other,20394379.0,
500,480301,3,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for Sprague-Dawley albino rat to anticonvulsant ED50 for Sprague-Dawley albino rat",Other,20394379.0,
501,480302,3,3,,103165722,4763,Inactive,,,,,"Anticonvulsant activity in albino mouse assessed as protection against subcutaneous metrazole-induced seizures up to 300 mg/kg, ip after 0.5 hrs",Other,20394379.0,
502,480303,3,3,,103165722,4763,Inactive,,,,,"Anticonvulsant activity in albino mouse assessed as protection against subcutaneous metrazole-induced seizures up to 300 mg/kg, ip after 4 hrs",Other,20394379.0,
503,481697,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant in ip dosed mouse assessed as protection against maximum electric stimulus-induced seizures,Other,20116141.0,
504,481698,3,3,,103165722,4763,Unspecified,,,,,Neurotoxicity against ip dosed mouse by rotarod ataxia test,Other,20116141.0,
505,481699,3,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for ip dosed mouse to ED50 for maximum electric stimulus-induced seizure in ip dosed mouse",Other,20116141.0,
506,485270,1,1,,51087546,4763,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
507,485272,1,1,,51087546,4763,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
508,485273,2,1,,51087546,4763,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
509,485275,1,3,,51087546,4763,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
510,485281,1,1,,29215458,4763,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
511,485290,1,1,,29215458,4763,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
512,485290,1,1,,51087546,4763,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
513,485341,1,1,,51087546,4763,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
514,485346,1,1,,51087546,4763,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
515,485346,1,1,,51087546,4763,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
516,485349,1,1,,51087546,4763,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
517,485353,2,1,,51087546,4763,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
518,485360,1,1,,51087546,4763,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
519,485367,1,2,,51087546,4763,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
520,487178,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Albino mouse assessed as protection against maximal electric shock-induced seizure after 0.5 hrs,Other,20211511.0,
521,487179,6,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Albino mouse assessed as protection against maximal electric shock-induced seizure after 4 hrs,Other,20211511.0,
522,487182,3,4,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Albino mouse assessed as minimal motor impairment after 0.5 hrs by rotarod test,Other,20211511.0,
523,487183,3,4,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Albino mouse assessed as minimal motor impairment after 4 hrs by rotarod test,Other,20211511.0,
524,487186,3,3,,103165722,4763,Inactive,,,,,"Anticonvulsant activity in Albino mouse assessed as protection against scPTZ-induced seizure at 300 mg/kg, ip after 0.5 hrs",Other,20211511.0,
525,487187,3,3,,103165722,4763,Inactive,,,,,"Anticonvulsant activity in Albino mouse assessed as protection against scPTZ-induced seizure at 300 mg/kg, ip after 4 hrs",Other,20211511.0,
526,488837,1,1,,51087546,4763,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
527,488839,1,1,,51087546,4763,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
528,488839,1,1,,51087546,4763,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
529,488847,1,3,,51087546,4763,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
530,488862,1,1,,51087546,4763,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
531,488890,1,2,,51087546,4763,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
532,488895,1,2,,51087546,4763,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
533,488896,1,1,,51087546,4763,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
534,488899,1,1,,51087546,4763,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
535,488965,1,2,,51087546,4763,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
536,488966,1,1,,51087546,4763,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
537,489030,2,1,,51087546,4763,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
538,489031,2,1,,51087546,4763,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
539,492947,1,1,,51087546,4763,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
540,492953,1,1,,51087546,4763,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
541,492956,1,1,,51087546,4763,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
542,492961,1,1,,29215458,4763,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
543,492967,1,2,,99302075,4763,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
544,492972,1,1,,51087546,4763,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
545,493005,1,1,,51087546,4763,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
546,493008,1,1,,51087546,4763,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
547,493008,1,1,,51087546,4763,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
548,493008,1,1,,51087546,4763,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
549,493008,1,1,,51087546,4763,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
550,493011,1,1,,51087546,4763,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
551,493012,1,1,,51087546,4763,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
552,493014,1,1,,51087546,4763,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
553,493036,1,2,,51087546,4763,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
554,493087,1,1,,51087546,4763,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
555,493091,1,1,,51087546,4763,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
556,493098,1,1,,51087546,4763,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
557,493131,1,1,,51087546,4763,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
558,493160,1,1,,51087546,4763,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
559,493162,1,2,,99302075,4763,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
560,493187,1,2,,51087546,4763,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
561,493244,1,1,,51087546,4763,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
562,493244,1,1,,51087546,4763,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
563,493244,1,1,,51087546,4763,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
564,493244,1,1,,51087546,4763,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
565,496045,2,9,,103165722,4763,Unspecified,117144.0,1544.0,,,Induction of CYP1A2 in human hepatocytes at 1000 uM after 72 hrs relative to control,Other,19933795.0,
566,496051,2,10,,103165722,4763,Unspecified,117205.0,1555.0,,,Induction of CYP2B6 in human hepatocytes at 1000 uM after 72 hrs relative to control,Other,19933795.0,
567,496057,2,10,,103165722,4763,Unspecified,116241312.0,1576.0,,,Induction of CYP3A4 in human hepatocytes at 1000 uM after 72 hrs relative to control,Other,19933795.0,
568,497227,5,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino Carworth Farms number 1 mouse assessed as protection against maximal electroshock-induced seizure,Other,20614888.0,
569,497229,2,4,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed albino Carworth Farms number 1 mouse by rotarod test,Other,20614888.0,
570,497230,2,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of neurotoxicity TD50 to anticonvulsant ED50 for ip dosed albino Carworth Farms number 1 mouse",Other,20614888.0,
571,497231,5,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizure,Other,20614888.0,
572,497232,2,4,,103165722,4763,Unspecified,,,,,Neurotoxicity in po dosed albino Sprague-Dawley rat by rotarod test,Other,20614888.0,
573,497233,2,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of neurotoxicity TD50 to anticonvulsant ED50 for po dosed albino Spague-Dawley rat",Other,20614888.0,
574,504326,1,2,,51087546,4763,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
575,504326,1,2,,51087546,4763,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
576,504327,1,1,,29215458,4763,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
577,504327,1,1,,51087546,4763,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
578,504329,1,1,,51087546,4763,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
579,504332,1,1,,29215458,4763,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
580,504339,1,1,,51087546,4763,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
581,504357,1,1,,51087546,4763,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
582,504357,1,1,,51087546,4763,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
583,504411,1,1,,51087546,4763,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
584,504414,1,1,,51087546,4763,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
585,504414,1,1,,51087546,4763,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
586,504423,1,1,,51087546,4763,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
587,504441,1,1,,51087546,4763,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
588,504444,1,1,,51087546,4763,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
589,504454,1,3,,51087546,4763,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
590,504462,1,1,,51087546,4763,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
591,504466,1,1,,51087546,4763,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
592,504467,1,1,,51087546,4763,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
593,504490,1,2,,51087546,4763,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
594,504523,1,1,,51087546,4763,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
595,504523,1,1,,51087546,4763,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
596,504558,1,1,,51087546,4763,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
597,504577,2,2,,51087546,4763,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
598,504582,2,1,,51087546,4763,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
599,504634,1,1,,51087546,4763,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
600,504648,1,1,,51087546,4763,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
601,504690,1,3,,51087546,4763,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
602,504692,2,2,,51087546,4763,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
603,504700,1,1,,51087546,4763,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
604,504700,1,1,,51087546,4763,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
605,504706,1,1,,51087546,4763,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
606,504707,1,1,,51087546,4763,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
607,504707,1,1,,51087546,4763,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
608,504720,1,1,,51087546,4763,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
609,504734,1,1,,51087546,4763,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
610,504749,1,3,,29215458,4763,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
611,504749,1,3,1.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
612,504749,1,3,2.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
613,504749,1,3,3.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
614,504749,1,3,4.0,29215458,4763,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
615,504749,1,3,5.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
616,504749,1,3,6.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
617,504749,1,3,7.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
618,504749,1,3,8.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
619,504749,1,3,9.0,29215458,4763,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
620,504749,1,3,10.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
621,504749,1,3,11.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
622,504749,1,3,12.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
623,504749,1,3,13.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
624,504749,1,3,14.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
625,504749,1,3,15.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
626,504749,1,3,16.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
627,504749,1,3,17.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
628,504749,1,3,18.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
629,504749,1,3,19.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
630,504749,1,3,20.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
631,504749,1,3,21.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
632,504749,1,3,22.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
633,504749,1,3,23.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
634,504749,1,3,24.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
635,504749,1,3,25.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
636,504749,1,3,26.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
637,504749,1,3,27.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
638,504749,1,3,28.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
639,504749,1,3,29.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
640,504749,1,3,30.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
641,504749,1,3,31.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
642,504749,1,3,32.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
643,504749,1,3,33.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
644,504749,1,3,34.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
645,504749,1,3,35.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
646,504749,1,3,36.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
647,504749,1,3,37.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
648,504749,1,3,38.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
649,504749,1,3,39.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
650,504749,1,3,40.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
651,504749,1,3,41.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
652,504749,1,3,42.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
653,504749,1,3,43.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
654,504749,1,3,44.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
655,504749,1,3,45.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
656,504749,1,3,46.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
657,504749,1,3,47.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
658,504749,1,3,48.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
659,504749,1,3,49.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
660,504749,1,3,50.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
661,504749,1,3,51.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
662,504749,1,3,52.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
663,504749,1,3,53.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
664,504749,1,3,54.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
665,504749,1,3,55.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
666,504749,1,3,56.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
667,504749,1,3,57.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
668,504749,1,3,58.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
669,504749,1,3,59.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
670,504749,1,3,60.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
671,504749,1,3,61.0,29215458,4763,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
672,504766,2,1,,51087546,4763,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
673,504775,1,1,,51087546,4763,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
674,504803,1,1,,51087546,4763,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
675,504810,1,2,,51087546,4763,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
676,504812,1,2,,51087546,4763,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
677,504832,1,1,,29215458,4763,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
678,504834,1,1,,29215458,4763,Inconclusive,,,4.2562,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
679,504842,1,1,,51087546,4763,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
680,504845,1,1,,51087546,4763,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
681,504847,1,1,,29215458,4763,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
682,504847,1,1,,51087546,4763,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
683,504865,1,1,,29215458,4763,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
684,504884,1,2,,51087546,4763,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
685,504891,1,1,,51087546,4763,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
686,504894,1,1,,51087546,4763,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
687,504937,1,2,,51087546,4763,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
688,519275,2,4,,103165722,4763,Unspecified,,,,,Increase in Pgh1 expression in chloroquine-resistant Plasmodium falciparum R1H6/2 by Western blot relative to untreated control,Other,18195056.0,
689,519276,2,4,,103165722,4763,Unspecified,,,,,Increase in Pgh1 expression in chloroquine-sensitive Plasmodium falciparum K1AM by Western blot relative to untreated control,Other,18195056.0,
690,519277,2,4,,103165722,4763,Unspecified,,,,,Increase in Pgh1 expression chloroquine-sensitive Plasmodium falciparum K1Hf by Western blot relative to untreated control,Other,18195056.0,
691,519278,2,3,,103165722,4763,Inactive,,,,,Increase in PfCRT expression in chloroquine-resistant Plasmodium falciparum R1H6/2 by Western blot relative to untreated control,Other,18195056.0,
692,519279,2,3,,103165722,4763,Inactive,,,,,Increase in PfCRT expression in chloroquine-sensitive Plasmodium falciparum K1AM by Western blot relative to untreated control,Other,18195056.0,
693,519280,2,3,,103165722,4763,Inactive,,,,,Increase in PfCRT expression chloroquine-sensitive Plasmodium falciparum K1Hf by Western blot relative to untreated control,Other,18195056.0,
694,540209,4,3,,103165722,4763,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
695,540210,4,3,,103165722,4763,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
696,540211,2,5,,103165722,4763,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
697,540212,4,3,,103165722,4763,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
698,540213,4,3,,103165722,4763,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
699,540235,1,3,,103165722,4763,Inactive,,,,,Phospholipidosis-negative literature compound,Other,17428028.0,
700,540253,1,1,,51087546,4763,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
701,540253,1,1,,51087546,4763,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
702,540253,1,1,,51087546,4763,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
703,540263,1,1,,51087546,4763,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
704,540263,1,1,,51087546,4763,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
705,540267,1,1,,51087546,4763,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
706,540295,1,1,,51087546,4763,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
707,540303,1,1,,51087546,4763,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
708,540303,1,1,,51087546,4763,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
709,540303,1,1,,51087546,4763,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
710,540308,1,1,,51087546,4763,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
711,540317,1,1,,51087546,4763,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
712,540336,1,1,,51087546,4763,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
713,540336,1,1,,51087546,4763,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
714,540364,1,2,,51087546,4763,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
715,545525,1,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for mouse to ED50 for inhibition of maximal electroshock-induced seizure in mouse",Other,20947222.0,
716,545526,1,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for mouse to ED50 for inhibition of subcutaneous pentylenetetrazole-induced seizure in mouse",Other,20947222.0,
717,545527,4,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed mouse assessed as inhibition of maximum electric shock-induced hind limb tonic extension,Other,20947222.0,
718,545528,4,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed mouse assessed as inhibition of PTZ-induced clonic seizure,Other,20947222.0,
719,545529,1,3,,103165722,4763,Unspecified,,,,,Toxicity against ip dosed mouse,Other,20947222.0,
720,576612,7,5,,103165722,4763,Unspecified,7531135.0,3757.0,3019.95,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
721,588208,2,3,,103165722,4763,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
722,588211,2,3,,103165722,4763,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
723,588212,2,3,,103165722,4763,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
724,588213,2,3,,103165722,4763,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
725,588220,2,3,,103165722,4763,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
726,588334,1,1,,51087546,4763,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
727,588335,1,1,,51087546,4763,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
728,588352,1,2,,51087546,4763,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
729,588354,1,1,,51087546,4763,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
730,588358,1,2,,51087546,4763,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
731,588391,1,1,,51087546,4763,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
732,588405,1,1,,51087546,4763,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
733,588413,1,2,,51087546,4763,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
734,588436,1,1,,51087546,4763,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
735,588453,1,1,,51087546,4763,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
736,588456,1,1,,51087546,4763,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
737,588458,1,1,,51087546,4763,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
738,588473,1,1,,51087546,4763,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
739,588473,1,1,,51087546,4763,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
740,588475,1,2,,51087546,4763,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
741,588475,1,2,,51087546,4763,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
742,588478,1,2,,124813340,4763,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
743,588489,1,1,,51087546,4763,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
744,588492,1,1,,51087546,4763,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
745,588493,1,2,,51087546,4763,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
746,588497,1,2,,51087546,4763,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
747,588497,1,2,,51087546,4763,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
748,588497,1,2,,51087546,4763,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
749,588499,1,3,,51087546,4763,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
750,588499,1,3,,51087546,4763,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
751,588499,1,3,,51087546,4763,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
752,588501,1,2,,51087546,4763,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
753,588501,1,2,,51087546,4763,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
754,588501,1,2,,51087546,4763,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
755,588549,1,1,,51087546,4763,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
756,588579,1,1,,29215458,4763,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
757,588579,1,1,,51087546,4763,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
758,588590,1,1,,51087546,4763,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
759,588591,1,1,,51087546,4763,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
760,588621,1,1,,51087546,4763,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
761,588664,1,2,,51087546,4763,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
762,588664,1,2,,51087546,4763,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
763,588674,1,2,,51087546,4763,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
764,588689,1,1,,51087546,4763,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
765,588692,2,1,,51087546,4763,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
766,588726,1,2,,51087546,4763,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
767,588727,1,1,,51087546,4763,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
768,588795,1,1,,51087546,4763,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
769,588814,1,3,,51087546,4763,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
770,588819,1,4,,51087546,4763,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
771,588834,2,1,,144205266,4763,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
772,588850,1,1,,51087546,4763,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
773,588852,1,3,,51087546,4763,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
774,588855,1,1,,51087546,4763,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
775,588856,1,1,,51087546,4763,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
776,589022,1,10,,103165722,4763,Unspecified,341941191.0,12355.0,,,Constitutive androstane receptor indirect activator,Other,,
777,589023,1,10,,103165722,4763,Unspecified,49066046.0,9970.0,,,Constitutive androstane receptor indirect activator,Other,,
778,589025,1,10,,103165722,4763,Unspecified,6093860.0,8856.0,,,Pregnane X receptor agonist,Other,,
779,589026,1,10,,103165722,4763,Unspecified,6093861.0,18171.0,,,Pregnane X receptor agonist,Other,,
780,589051,1,10,,103165722,4763,Unspecified,117205.0,1555.0,,,"Clinically relevant inducers of human liver microsomal P450 enzymes, isoform CYP2B6",Other,,
781,589052,1,11,,103165722,4763,Unspecified,117225.0,1558.0,,,"Clinically relevant inducers of human liver microsomal P450 enzymes, isoform CYP2C8",Other,,
782,589053,1,10,,103165722,4763,Unspecified,6686268.0,1559.0,,,"Clinically relevant inducers of human liver microsomal P450 enzymes, isoform CYP2C9",Other,,
783,589054,1,10,,103165722,4763,Unspecified,60416369.0,1557.0,,,"Clinically relevant inducers of human liver microsomal P450 enzymes, isoform CYP2C19",Other,,
784,589056,1,10,,103165722,4763,Unspecified,116241312.0,1576.0,,,"Clinically relevant inducers of human liver microsomal P450 enzymes, isoform CYP3A4",Other,,
785,602123,1,1,,51087546,4763,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
786,602141,1,1,,51087546,4763,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
787,602162,1,1,,51087546,4763,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
788,602163,1,1,,51087546,4763,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
789,602179,1,2,,51087546,4763,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
790,602229,1,1,,51087546,4763,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
791,602233,1,1,,51087546,4763,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
792,602244,1,2,,51087546,4763,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
793,602247,1,2,,51087546,4763,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
794,602248,1,2,,51087546,4763,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
795,602250,1,2,,51087546,4763,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
796,602252,1,1,,51087546,4763,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
797,602252,1,1,,51087546,4763,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
798,602261,1,1,,51087546,4763,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
799,602274,1,2,,51087546,4763,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
800,602281,1,1,,51087546,4763,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
801,602281,1,1,,51087546,4763,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
802,602310,1,2,,51087546,4763,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
803,602313,1,1,,51087546,4763,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
804,602329,1,1,,51087546,4763,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
805,602332,1,1,,29215458,4763,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
806,602332,1,1,,51087546,4763,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
807,602340,1,2,,51087546,4763,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
808,602342,2,1,,51087546,4763,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
809,602346,1,1,,51087546,4763,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
810,602363,1,1,,51087546,4763,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
811,602393,1,1,,51087546,4763,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
812,602396,1,2,,51087546,4763,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
813,602399,1,2,,51087546,4763,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
814,602405,1,1,,51087546,4763,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
815,602410,1,1,,51087546,4763,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
816,602429,1,1,,51087546,4763,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
817,602438,1,1,,51087546,4763,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
818,602440,1,1,,51087546,4763,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
819,602449,1,2,,51087546,4763,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
820,602481,1,1,,51087546,4763,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
821,603953,1,3,,103165722,4763,Unspecified,,,,,"In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
822,608517,1,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in Kunming mouse to ED50 for inhibition of MES-induced seizures in Kunming mouse",Other,21536355.0,
823,608518,1,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Kunming mouse by rotarod test,Other,21536355.0,
824,608519,4,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity against maximal electric shock-induced seizures in ip dosed Kunming mouse assessed as median effective dose,Other,21536355.0,
825,619692,4,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizure after 30 mins,Other,21861463.0,
826,619695,1,4,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed albino CF1 mouse assessed as median neurological impairing dose after 30 mins,Other,21861463.0,
827,619696,1,4,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for ip dosed albino CF1 mouse to ED50 for ip dosed albino CF1 mouse by maximal electroshock test",Other,21861463.0,
828,619697,4,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock seizure,Other,21861463.0,
829,619698,1,4,,103165722,4763,Unspecified,,,,,Toxicity in po dosed albino Sprague-Dawley rat assessed as behavioural toxicity,Other,21861463.0,
830,619699,1,4,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for po dosed albino Sprague-Dawley rat to ED50 for po dosed albino Sprague-Dawley rat by maximal electroshock test",Other,21861463.0,
831,619778,1,4,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF1 mouse assessed as time of peak effect for protection against maximal electroshock-induced seizure,Other,21861463.0,
832,619781,1,4,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed albino CF1 mouse assessed as time of peak effect for median neurological impairing,Other,21861463.0,
833,619782,1,4,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as time of peak effect for protection against maximal electroshock seizure,Other,21861463.0,
834,619783,1,4,,103165722,4763,Unspecified,,,,,Toxicity in po dosed albino Sprague-Dawley rat assessed as time of peak effect for behavioural toxicity,Other,21861463.0,
835,621622,4,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizures in presence of 50 miliamperes of electric current,Other,21861466.0,
836,621623,1,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF1 mouse assessed as time of peak effect by maximal electroshock seizures test in presence of 50 miliamperes of electric current,Other,21861466.0,
837,621624,1,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed albino CF1 mouse assessed as minimal motor coordination impairment by rotarod test,Other,21861466.0,
838,621625,1,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for albino CF1 mouse by rotarod test to ED50 for albino CF1 mouse by maximal electroshock seizures test",Other,21861466.0,
839,621649,4,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizures in presence of 150 miliamperes of electric current,Other,21861466.0,
840,621650,1,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as time of peak effect by maximal electroshock seizures test in presence of 150 miliamperes of electric current,Other,21861466.0,
841,621651,1,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in po dosed albino Sprague-Dawley rat,Other,21861466.0,
842,621652,1,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for albino Sprague-Dawley rat to ED50 for albino Sprague-Dawley rat by maximal electroshock seizures test",Other,21861466.0,
843,621653,1,3,,103165722,4763,Unspecified,,,,,Behavioral toxicity in po dosed albino Sprague-Dawley rat assessed as time of peak effect,Other,21861466.0,
844,621654,1,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed albino CF1 mouse assessed as time of peak effect by rotarod test,Other,21861466.0,
845,623870,1,1,,51087546,4763,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
846,623870,1,1,,51087546,4763,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
847,623877,1,1,,51087546,4763,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
848,623901,1,1,,51087546,4763,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
849,624030,1,2,,29215458,4763,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
850,624031,1,2,,29215458,4763,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
851,624032,1,2,,29215458,4763,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
852,624037,1,3,,51087546,4763,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
853,624038,1,3,,51087546,4763,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
854,624040,1,3,,51087546,4763,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
855,624044,1,2,,29215458,4763,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
856,624125,1,4,,51087546,4763,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
857,624126,1,3,,51087546,4763,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
858,624127,1,2,,51087546,4763,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
859,624168,1,1,,51087546,4763,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
860,624169,1,1,,51087546,4763,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
861,624170,1,1,,29215458,4763,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
862,624170,1,1,,51087546,4763,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
863,624171,1,1,,51087546,4763,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
864,624172,1,1,,29215458,4763,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
865,624172,1,1,,51087546,4763,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
866,624173,1,3,,29215458,4763,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
867,624173,1,3,,51087546,4763,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
868,624178,1,1,,51087546,4763,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
869,624202,1,1,,51087546,4763,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
870,624204,1,2,,51087546,4763,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
871,624246,1,1,,51087546,4763,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
872,624263,1,1,,51087546,4763,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
873,624263,1,1,,51087546,4763,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
874,624267,1,2,,51087546,4763,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
875,624267,1,2,,51087546,4763,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
876,624268,1,3,,51087546,4763,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
877,624288,1,1,,51087546,4763,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
878,624296,1,1,,29215458,4763,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
879,624296,1,1,,51087546,4763,Inactive,7705682.0,51053.0,1.8356,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
880,624297,1,1,,29215458,4763,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
881,624297,1,1,,51087546,4763,Inconclusive,7705682.0,51053.0,20.5962,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
882,624304,1,2,,51087546,4763,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
883,624330,1,2,,51087546,4763,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
884,624352,1,1,,51087546,4763,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
885,624354,1,1,,51087546,4763,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
886,624377,1,1,,51087546,4763,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
887,624414,1,1,,51087546,4763,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
888,624415,1,2,,51087546,4763,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
889,624416,1,1,,51087546,4763,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
890,624417,1,1,,51087546,4763,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
891,624418,1,1,,51087546,4763,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
892,624463,1,1,,51087546,4763,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
893,624464,1,1,,51087546,4763,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
894,624465,1,1,,51087546,4763,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
895,624466,1,3,,51087546,4763,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
896,624467,1,1,,51087546,4763,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
897,624483,1,1,,51087546,4763,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
898,624606,1,9,,103165722,4763,Unspecified,136729.0,54658.0,,,Specific activity of expressed human recombinant UGT1A1,Other,10836148.0,
899,625144,5,5,,103165722,4763,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
900,625145,4,7,,103165722,4763,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
901,625146,5,5,,103165722,4763,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
902,625147,4,7,,103165722,4763,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
903,625148,4,7,,103165722,4763,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
904,625149,4,7,,103165722,4763,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
905,625150,5,5,,103165722,4763,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
906,625151,4,7,,103165722,4763,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
907,625152,4,7,,103165722,4763,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
908,625153,4,7,,103165722,4763,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
909,625154,4,7,,103165722,4763,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
910,625155,4,7,,103165722,4763,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
911,625156,1,9,,103165722,4763,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
912,625157,6,2,,103165722,4763,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
913,625158,3,4,,103165722,4763,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
914,625159,5,5,,103165722,4763,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
915,625160,1,9,,103165722,4763,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
916,625161,4,7,,103165722,4763,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
917,625162,4,7,,103165722,4763,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
918,625163,4,7,,103165722,4763,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
919,625164,1,6,,103165722,4763,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
920,625165,3,4,,103165722,4763,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
921,625166,3,4,,103165722,4763,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
922,625167,5,5,,103165722,4763,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
923,625168,4,7,,103165722,4763,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
924,625169,1,6,,103165722,4763,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
925,625170,3,4,,103165722,4763,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
926,625171,4,7,,103165722,4763,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
927,625172,4,7,,103165722,4763,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
928,625173,5,5,,103165722,4763,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
929,625174,5,5,,103165722,4763,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
930,625175,5,5,,103165722,4763,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
931,625176,1,9,,103165722,4763,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
932,625177,5,5,,103165722,4763,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
933,625178,5,5,,103165722,4763,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
934,625179,1,9,,103165722,4763,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
935,625180,5,5,,103165722,4763,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
936,625181,5,5,,103165722,4763,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
937,625182,5,5,,103165722,4763,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
938,625183,5,5,,103165722,4763,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
939,625184,5,5,,103165722,4763,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
940,625185,5,5,,103165722,4763,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
941,625186,5,5,,103165722,4763,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
942,625187,5,5,,103165722,4763,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
943,625188,1,9,,103165722,4763,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
944,625189,1,7,,103165722,4763,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
945,625190,4,5,,103165722,4763,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
946,625191,4,7,,103165722,4763,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
947,625192,4,7,,103165722,4763,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
948,625193,5,5,,103165722,4763,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
949,625194,4,7,,103165722,4763,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
950,625195,4,7,,103165722,4763,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
951,625196,5,6,,103165722,4763,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
952,625197,3,4,,103165722,4763,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
953,625198,4,7,,103165722,4763,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
954,625199,4,7,,103165722,4763,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
955,625200,4,7,,103165722,4763,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
956,625201,4,7,,103165722,4763,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
957,625202,4,7,,103165722,4763,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
958,625203,4,7,,103165722,4763,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
959,625204,4,7,,103165722,4763,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
960,625205,4,7,,103165722,4763,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
961,625206,4,7,,103165722,4763,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
962,625207,4,7,,103165722,4763,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
963,625208,5,5,,103165722,4763,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
964,625209,4,7,,103165722,4763,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
965,625210,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
966,625211,1,6,,103165722,4763,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
967,625212,3,4,,103165722,4763,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
968,625213,4,7,,103165722,4763,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
969,625214,1,9,,103165722,4763,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
970,625215,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
971,625216,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
972,625217,4,7,,103165722,4763,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
973,625218,4,7,,103165722,4763,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
974,625219,3,4,,103165722,4763,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
975,625220,4,7,,103165722,4763,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
976,625221,4,7,,103165722,4763,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
977,625222,4,7,,103165722,4763,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
978,625223,4,7,,103165722,4763,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
979,625224,3,4,,103165722,4763,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
980,625225,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
981,625226,4,7,,103165722,4763,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
982,625227,4,7,,103165722,4763,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
983,625228,4,7,,103165722,4763,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
984,625229,5,5,,103165722,4763,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
985,625230,1,6,,103165722,4763,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
986,625231,4,7,,103165722,4763,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
987,625232,1,9,,103165722,4763,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
988,625233,4,7,,103165722,4763,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
989,625234,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
990,625235,4,7,,103165722,4763,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
991,625236,5,5,,103165722,4763,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
992,625237,4,7,,103165722,4763,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
993,625238,4,7,,103165722,4763,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
994,625239,4,7,,103165722,4763,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
995,625240,1,9,,103165722,4763,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
996,625241,4,7,,103165722,4763,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
997,625242,4,7,,103165722,4763,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
998,625243,5,5,,103165722,4763,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
999,625244,5,5,,103165722,4763,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1000,625245,5,5,,103165722,4763,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1001,625246,1,9,,103165722,4763,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1002,625247,5,5,,103165722,4763,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1003,625248,5,5,,103165722,4763,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1004,625249,5,5,,103165722,4763,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1005,625250,5,5,,103165722,4763,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1006,625251,5,5,,103165722,4763,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1007,625252,4,7,,103165722,4763,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1008,625253,4,7,,103165722,4763,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1009,625254,4,7,,103165722,4763,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1010,625255,4,7,,103165722,4763,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1011,625256,4,7,,103165722,4763,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1012,625257,4,7,,103165722,4763,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1013,625258,4,7,,103165722,4763,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1014,625259,4,7,,103165722,4763,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1015,625260,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1016,625261,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1017,625262,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1018,625263,4,7,,103165722,4763,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1019,625264,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1020,625265,1,6,,103165722,4763,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1021,625266,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1022,625267,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1023,625268,4,2,,103165722,4763,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1024,625268,4,2,,103165722,4763,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1025,625268,4,2,,103165722,4763,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1026,625268,4,2,,103165722,4763,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1027,625269,4,7,,103165722,4763,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1028,625270,4,7,,103165722,4763,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1029,625271,5,5,,103165722,4763,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1030,625272,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1031,625273,4,6,,103165722,4763,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1032,625274,1,6,,103165722,4763,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1033,625275,3,4,,103165722,4763,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1034,625277,1,3,,103165722,4763,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
1035,626714,3,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino Carworth Farms No.1 mouse assessed as protection against maximal electroshock-induced seizure after 0.25 hrs,Other,21862182.0,
1036,626715,3,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino Carworth Farms No.1 mouse assessed as protection against subcutaneous metrazol-induced seizure after 0.25 hrs,Other,21862182.0,
1037,626716,1,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed albino Carworth Farms No.1 mouse assessed as motor impairment after 0.25 hrs by rotarod test,Other,21862182.0,
1038,626717,1,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for albino Carworth Farms No.1 mouse to ED50 for albino Carworth Farms No.1 mouse by maximal electroshock-induced seizure test",Other,21862182.0,
1039,626718,1,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino Carworth Farms No.1 mouse assessed as time needs to show peak effect for protection against maximal electroshock-induced seizure,Other,21862182.0,
1040,626719,3,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino Carworth Farms No.1 mouse assessed as protection against electric-current for 3 secs-induced seizure after 0.25 hrs by 6Hz minimal clonic seizure test,Other,21862182.0,
1041,626720,1,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for albino Carworth Farms No.1 mouse to ED50 for albino Carworth Farms No.1 mouse by 6Hz minimal clonic seizure test",Other,21862182.0,
1042,626721,1,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino Carworth Farms No.1 mouse assessed as time needs to show peak effect for electric-current for 3 secs-induced seizure after 0.25 hrs by 6Hz minimal clonic seizure test,Other,21862182.0,
1043,626747,3,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizure after 0.25 hrs,Other,21862182.0,
1044,626748,3,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as protection against subcutaneous metrazol-induced seizure after 0.25 hrs,Other,21862182.0,
1045,626749,1,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in po dosed albino Sprague-Dawley rat assessed as motor impairment after 0.25 hrs by rotarod test,Other,21862182.0,
1046,626750,1,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for albino Sprague-Dawley rat to ED50 for albino Sprague-Dawley rat by maximal electroshock-induced seizure test",Other,21862182.0,
1047,626751,1,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat assessed as time needs to show peak effect for protection against maximal electroshock-induced seizure after 0.25 hrs,Other,21862182.0,
1048,637069,1,4,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Kunming mouse assessed as minimal motor impairment after 0.5 hrs by rotarod test,Other,22236471.0,
1049,637073,3,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Kunming mouse assessed as protection against maximal electroshock-induced seizure,Other,22236471.0,
1050,637074,3,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Kunming mouse assessed as protection against subcutaneous pentylenetetrazole-induced seizure,Other,22236471.0,
1051,637075,1,4,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for ip dosed Kunming mouse to ED50 for ip dosed Kunming mouse by maximal electroshock seizure test",Other,22236471.0,
1052,637076,1,4,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for ip dosed Kunming mouse to ED50 for ip dosed Kunming mouse by subcutaneous pentylenetetrazole induced seizure test",Other,22236471.0,
1053,643383,1,6,,103165722,4763,Unspecified,,,,,Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy,Other,22122484.0,
1054,651550,1,1,,51087546,4763,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1055,651560,1,1,,51087546,4763,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1056,651572,1,2,,51087546,4763,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1057,651602,1,1,,51087546,4763,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1058,651602,1,1,,51087546,4763,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1059,651602,1,1,,51087546,4763,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1060,651631,4,1,,144205266,4763,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1061,651631,4,1,,144207708,4763,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1062,651632,4,1,,144205266,4763,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1063,651632,4,1,,144207708,4763,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1064,651633,4,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1065,651633,4,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1066,651634,4,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1067,651634,4,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1068,651635,1,3,,51087546,4763,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1069,651636,1,1,,51087546,4763,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1070,651640,1,1,,51087546,4763,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1071,651644,1,1,,51087546,4763,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1072,651647,1,1,,51087546,4763,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1073,651654,1,1,,51087546,4763,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1074,651658,1,1,,51087546,4763,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1075,651661,2,1,,51087546,4763,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1076,651687,1,1,,51087546,4763,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1077,651699,1,1,,51087546,4763,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1078,651699,1,1,,51087546,4763,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1079,651702,1,2,,51087546,4763,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1080,651710,1,1,,51087546,4763,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1081,651711,2,1,,51087546,4763,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1082,651718,1,2,,51087546,4763,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1083,651719,1,2,,51087546,4763,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1084,651723,1,1,,51087546,4763,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1085,651724,1,1,,51087546,4763,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1086,651725,1,1,,51087546,4763,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1087,651768,1,2,,51087546,4763,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1088,651800,1,1,,51087546,4763,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1089,651819,1,1,,51087546,4763,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1090,651820,1,1,,51087546,4763,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1091,651821,2,4,,51087546,4763,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1092,651957,1,1,,51087546,4763,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1093,651958,1,1,,51087546,4763,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1094,651965,1,1,,51087546,4763,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1095,651999,1,1,,51087546,4763,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1096,652010,1,1,,51087546,4763,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1097,652017,1,1,,51087546,4763,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1098,652025,1,1,,51087546,4763,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1099,652039,1,1,,51087546,4763,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1100,652048,1,2,,51087546,4763,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1101,652048,1,2,,144205266,4763,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1102,652051,1,1,,51087546,4763,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1103,652051,1,1,,144205266,4763,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1104,652054,1,1,,51087546,4763,Active,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1105,652067,1,4,,51087546,4763,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1106,652104,1,1,,51087546,4763,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1107,652105,1,1,,51087546,4763,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1108,652106,1,1,,51087546,4763,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1109,652126,1,3,,51087546,4763,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1110,652162,2,1,,51087546,4763,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1111,652163,1,1,,51087546,4763,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1112,652197,1,1,,51087546,4763,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1113,652257,1,1,,51087546,4763,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1114,652953,2,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed mouse assessed as decrease in pentylenetetrazol-induced convulsions at 30 mins,Other,22401865.0,
1115,665864,2,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed NMRI mouse assessed as protection against maximal electroshock-induced seizure after 30 mins postdose,Other,22546207.0,
1116,665943,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed NMRI mouse after 30 mins by rotorod test,Other,22546207.0,
1117,665954,1,2,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for NMRI mouse to ED50 for anticonvulsant activity in ip dosed NMRI mouse by maximal electroshock seizure test",Other,22546207.0,
1118,666675,2,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Kunming mouse assessed as protection against maximal electroshock-induced seizures,Other,22727446.0,
1119,666676,2,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Kunming mouse assessed as protection against subcutaneous pentylenetetrazol-induced clonic seizures,Other,22727446.0,
1120,666677,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Kunming mouse measured 30 mins post compound administration by rotorod test,Other,22727446.0,
1121,666678,1,2,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in Kunming mouse to ED50 for protection against MES-induced seizures in Kunming mouse",Other,22727446.0,
1122,666679,1,2,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in Kunming mouse to ED50 for protection against subcutaneous pentylenetetrazol-induced clonic seizures in Kunming mouse",Other,22727446.0,
1123,678712,1,8,,103165722,4763,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
1124,678713,1,8,,103165722,4763,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
1125,678714,1,8,,103165722,4763,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1126,678715,1,8,,103165722,4763,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1127,678716,1,8,,103165722,4763,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
1128,678717,1,8,,103165722,4763,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
1129,678721,1,5,,103165722,4763,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
1130,678722,1,5,,103165722,4763,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
1131,679141,1,8,,103165722,4763,Unspecified,6016599.0,140668.0,,,"TP_TRANSPORTER: quantitative PCR in vivo, liver of SD rat",Other,12920174.0,
1132,679142,1,8,,103165722,4763,Unspecified,6016599.0,140668.0,,,"TP_TRANSPORTER: Western in vivo, liver of SD rat",Other,12920174.0,
1133,679143,1,8,,103165722,4763,Unspecified,6016599.0,140668.0,,,"TP_TRANSPORTER: Branched DNA Assay in vivo, liver of WKY rat",Other,14570762.0,
1134,679162,1,8,,103165722,4763,Unspecified,218526606.0,76408.0,,,"TP_TRANSPORTER: Branched DNA Assay in vivo, liver of mouse",Other,14570762.0,
1135,679181,1,8,,103165722,4763,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: Northern blot in vivo SD rat, liver",Other,11841808.0,
1136,679185,1,8,,103165722,4763,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: Northern blot in vitro, primary hepatocytes",Other,11841808.0,
1137,679484,1,8,,103165722,4763,Unspecified,12585136.0,83569.0,,,"TP_TRANSPORTER: Northern blot in vitro, primary hepatocytes",Other,11706036.0,
1138,679671,1,8,,103165722,4763,Unspecified,308153583.0,1244.0,,,TP_TRANSPORTER: Northern blot from HepG2 cells,Other,11323161.0,
1139,679672,1,7,,103165722,4763,Unspecified,338817955.0,12780.0,,,"TP_TRANSPORTER: Northern blot in vitro, primary hepatocytes",Other,11706036.0,
1140,679817,1,8,,103165722,4763,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: Western in vivo SD rat, liver",Other,11861969.0,
1141,679818,1,8,,103165722,4763,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: Western blot, H4IIE rat hepatoma cells",Other,9571149.0,
1142,679820,1,8,,103165722,4763,Unspecified,3219824.0,25303.0,,,TP_TRANSPORTER: Northern blot from H4IIE rat hepatoma cells,Other,9571149.0,
1143,679997,1,7,,103165722,4763,Unspecified,127792.0,24777.0,,,"TP_TRANSPORTER: Northern blot in vivo SD rat, liver",Other,10712264.0,
1144,680323,1,8,,103165722,4763,Unspecified,6016599.0,140668.0,,,"TP_TRANSPORTER: Western in vivo SD rat, liver",Other,10712264.0,
1145,680324,1,8,,103165722,4763,Unspecified,6016599.0,140668.0,,,"TP_TRANSPORTER: Northern blot in vivo SD rat, liver",Other,10712264.0,
1146,680328,1,8,,103165722,4763,Unspecified,7387886.0,81642.0,,,"TP_TRANSPORTER: Northern blot in vivo SD rat, liver",Other,10712264.0,
1147,680602,1,7,,103165722,4763,Unspecified,74761045.0,,,,TP_TRANSPORTER: Northern blot from HepG2 cells,Other,9738950.0,
1148,680646,1,8,,103165722,4763,Unspecified,1171883.0,50572.0,,,"TP_TRANSPORTER: Western in vivo SD rat, liver",Other,11451172.0,
1149,680649,1,8,,103165722,4763,Unspecified,1171883.0,50572.0,,,"TP_TRANSPORTER: Northern blot in vivo SD rat, liver",Other,11451172.0,
1150,680816,1,8,,103165722,4763,Unspecified,308153583.0,1244.0,,,"TP_TRANSPORTER: Western in vitro, primary hepatocytes",Other,11841808.0,
1151,680820,1,8,,103165722,4763,Unspecified,308153583.0,1244.0,,,"TP_TRANSPORTER: Northern blot in vitro, primary hepatocytes",Other,11841808.0,
1152,681166,1,8,,103165722,4763,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: Western blot, LS180 cell",Other,8632764.0,
1153,681495,1,7,,103165722,4763,Unspecified,81911503.0,,,,"TP_TRANSPORTER: Northern blot in vitro, primary hepatocytes",Other,11841808.0,
1154,681521,1,8,,103165722,4763,Unspecified,296439301.0,4363.0,,,TP_TRANSPORTER: Northern blot from HepG2 cells,Other,9738950.0,
1155,681856,1,8,,103165722,4763,Unspecified,3914190.0,170698.0,,,"TP_TRANSPORTER: Western in vivo SD rat, liver",Other,11451172.0,
1156,681858,1,8,,103165722,4763,Unspecified,3914190.0,170698.0,,,"TP_TRANSPORTER: Northern blot in vivo SD rat, liver",Other,11451172.0,
1157,682042,1,8,,103165722,4763,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: Western in vitro, primary hepatocytes",Other,11841808.0,
1158,682136,1,8,,103165722,4763,Unspecified,3914190.0,170698.0,,,"TP_TRANSPORTER: Western in vivo SD rat, liver",Other,11752118.0,
1159,686940,1,1,,51087546,4763,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
1160,686964,1,1,,51087546,4763,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
1161,686970,1,2,,51087546,4763,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
1162,686971,1,2,,51087546,4763,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
1163,686978,1,1,,51087546,4763,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1164,686978,1,1,,144205266,4763,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
1165,686979,1,1,,51087546,4763,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1166,686979,1,1,,144205266,4763,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
1167,686996,1,1,,51087546,4763,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1168,687014,1,1,,51087546,4763,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
1169,687016,1,1,,51087546,4763,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
1170,687765,2,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed CF1 mouse assessed as protection against maximal electroshock-induced seizure after 30 mins,Other,21639114.0,
1171,687767,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed CF1 mouse assessed as time of peak effect for protection against maximal electroshock-induced seizure,Other,21639114.0,
1172,687774,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed NMRI mouse assessed as minimal motor impairment after 30 mins,Other,21639114.0,
1173,687775,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed NMRI mouse assessed as time of peak effect for minimal motor impairment after 30 mins,Other,21639114.0,
1174,687785,2,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as protection against maximal electroshock-induced seizure after 30 mins,Other,21639114.0,
1175,687786,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed Sprague-Dawley rat assessed as time of peak effect for protection against maximal electroshock-induced seizure after 30 mins,Other,21639114.0,
1176,687787,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity in po dosed Sprague-Dawley rat assessed as minimal motor impairment after 30 mins by rotorod test,Other,21639114.0,
1177,687788,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity in po dosed Sprague-Dawley rat assessed as time of peak effect for minimal motor impairment after 30 mins by rotorod test,Other,21639114.0,
1178,687789,1,2,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for Sprague-Dawley rat to ED50 for Sprague-Dawley rat by maximal electroshock seizure test",Other,21639114.0,
1179,696701,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Swiss albino mouse assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 108 umol/kg, ip administered 30 mins before pentylenetetrazole challenge measured after 30 mins",Other,22118828.0,
1180,699539,1,7,,103165722,4763,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
1181,699540,1,7,,103165722,4763,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1182,699541,1,7,,103165722,4763,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
1183,720504,1,1,,51087546,4763,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
1184,720508,1,1,,51087546,4763,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1185,720509,1,1,,51087546,4763,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
1186,720511,1,1,,51087546,4763,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
1187,720516,2,1,,144205266,4763,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1188,720516,2,1,,144207708,4763,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
1189,720532,1,1,,144205266,4763,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
1190,720533,1,1,,144205266,4763,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
1191,720542,1,2,,51087546,4763,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
1192,720543,1,1,,51087546,4763,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
1193,720551,1,2,,51087546,4763,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
1194,720552,2,1,,144205266,4763,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1195,720552,2,1,,144207708,4763,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
1196,720553,1,2,,51087546,4763,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
1197,720579,2,1,,51087546,4763,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
1198,720580,1,1,,51087546,4763,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
1199,720582,1,1,,51087546,4763,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
1200,720596,1,1,,51087546,4763,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
1201,720634,2,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1202,720634,2,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
1203,720635,2,1,,144205266,4763,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1204,720635,2,1,,144207708,4763,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
1205,720637,2,1,,144205266,4763,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1206,720637,2,1,,144207708,4763,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
1207,720647,1,2,,51087546,4763,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
1208,720648,1,1,,51087546,4763,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
1209,720674,2,2,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1210,720674,2,2,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
1211,720675,2,2,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1212,720675,2,2,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
1213,720678,2,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1214,720678,2,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
1215,720679,2,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1216,720679,2,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
1217,720680,2,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1218,720680,2,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
1219,720681,2,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1220,720681,2,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
1221,720682,2,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1222,720682,2,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
1223,720683,2,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1224,720683,2,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
1225,720684,2,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1226,720684,2,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
1227,720685,2,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1228,720685,2,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
1229,720686,2,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1230,720686,2,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
1231,720687,2,2,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1232,720687,2,2,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
1233,720691,4,1,,144205266,4763,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1234,720691,4,1,,144207708,4763,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1235,720692,3,1,,144205266,4763,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1236,720692,3,1,,144207708,4763,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
1237,720693,3,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1238,720693,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1239,720700,1,4,,51087546,4763,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
1240,720702,1,1,,51087546,4763,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
1241,720704,1,4,,51087546,4763,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
1242,720706,1,2,,51087546,4763,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1243,720707,1,2,,51087546,4763,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1244,720708,1,2,,51087546,4763,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
1245,720709,1,2,,51087546,4763,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
1246,720711,1,2,,51087546,4763,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
1247,720719,2,1,,144205266,4763,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1248,720719,2,1,,144207708,4763,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1249,720725,2,1,,144205266,4763,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1250,720725,2,1,,144207708,4763,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1251,743012,3,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1252,743012,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1253,743014,3,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1254,743014,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1255,743015,3,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1256,743015,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1257,743033,3,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1258,743033,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1259,743035,2,1,,144205266,4763,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1260,743035,2,1,,144207708,4763,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1261,743036,2,1,,144205266,4763,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1262,743036,2,1,,144207708,4763,Inconclusive,124375976.0,367.0,1.1201,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1263,743040,3,1,,144205266,4763,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1264,743040,3,1,,144207708,4763,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1265,743041,3,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1266,743041,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1267,743042,3,1,,144205266,4763,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1268,743042,3,1,,144207708,4763,Inconclusive,124375976.0,367.0,55.6483,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1269,743053,2,1,,144205266,4763,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1270,743053,2,1,,144207708,4763,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1271,743054,2,1,,144205266,4763,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1272,743054,2,1,,144207708,4763,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1273,743063,2,1,,144205266,4763,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1274,743063,2,1,,144207708,4763,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1275,743064,3,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1276,743064,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1277,743065,3,1,,144205266,4763,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1278,743065,3,1,,144207708,4763,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1279,743066,3,1,,144205266,4763,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1280,743066,3,1,,144207708,4763,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1281,743067,2,1,,144205266,4763,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1282,743067,2,1,,144207708,4763,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1283,743069,2,1,,144205266,4763,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1284,743069,2,1,,144207708,4763,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1285,743074,2,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1286,743074,2,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1287,743075,2,1,,144205266,4763,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1288,743075,2,1,,144207708,4763,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1289,743077,2,1,,144205266,4763,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1290,743077,2,1,,144207708,4763,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1291,743078,2,1,,144205266,4763,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1292,743078,2,1,,144207708,4763,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1293,743079,3,1,,144205266,4763,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1294,743079,3,1,,144207708,4763,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1295,743080,3,1,,144205266,4763,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1296,743080,3,1,,144207708,4763,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1297,743081,3,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1298,743081,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1299,743083,3,1,,144205266,4763,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1300,743083,3,1,,144207708,4763,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1301,743084,3,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1302,743084,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1303,743085,3,1,,144205266,4763,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1304,743085,3,1,,144207708,4763,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1305,743086,3,1,,144205266,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1306,743086,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1307,743091,2,1,,144205266,4763,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1308,743091,2,1,,144207708,4763,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1309,743094,3,1,,144205266,4763,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1310,743094,3,1,,144207708,4763,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1311,743122,2,1,,144205266,4763,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1312,743122,2,1,,144207708,4763,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1313,743126,1,1,,51087546,4763,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
1314,743139,2,1,,144205266,4763,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1315,743139,2,1,,144207708,4763,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1316,743140,2,1,,144205266,4763,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1317,743140,2,1,,144207708,4763,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1318,743191,3,1,,144207708,4763,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1319,743194,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1320,743199,2,1,,144207708,4763,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1321,743202,4,1,,144207708,4763,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1322,743203,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1323,743209,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1324,743210,4,1,,144207708,4763,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1325,743211,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1326,743212,3,1,,144207708,4763,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1327,743213,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1328,743215,3,1,,144207708,4763,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1329,743217,3,1,,144207708,4763,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1330,743218,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1331,743219,3,1,,144207708,4763,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1332,743220,3,1,,144207708,4763,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1333,743221,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1334,743222,3,1,,144207708,4763,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1335,743223,3,1,,144207708,4763,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1336,743224,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1337,743225,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1338,743226,2,1,,144207708,4763,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1339,743227,2,1,,144207708,4763,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1340,743228,3,1,,144207708,4763,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1341,743239,2,1,,144207708,4763,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1342,743240,2,1,,144207708,4763,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1343,743241,2,1,,144207708,4763,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1344,743242,2,1,,144207708,4763,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1345,743244,1,1,,144205266,4763,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1346,743255,1,1,,51087546,4763,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
1347,743266,1,2,,51087546,4763,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
1348,743269,1,1,,51087546,4763,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1349,743269,1,1,,51087546,4763,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
1350,743279,1,2,,51087546,4763,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
1351,743287,1,1,,51087546,4763,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
1352,743398,1,1,,51087546,4763,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
1353,759084,1,1,,103165722,4763,Unspecified,,,,,Toxicity in po dosed albino Sprague-Dawley rat assessed as behavioral toxicity after 0.5 hrs,Other,23772678.0,
1354,759089,1,1,,103165722,4763,Unspecified,,,,,Anticonvulsant activity against po dosed albino Sprague-Dawley rat after 5 hrs by maximal electroshock seizure test,Other,23772678.0,
1355,759100,1,1,,103165722,4763,Unspecified,,,,,Toxicity in ip dosed albino CF1 mouse after 0.5 hrs by rotorod test,Other,23772678.0,
1356,759119,1,1,,103165722,4763,Unspecified,,,,,Anticonvulsant activity against ip dosed albino CF1 mouse after 1 hr by maximal electroshock seizure test,Other,23772678.0,
1357,768829,1,3,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for BALB/c mouse by rotarod test to ED50 for BALB/c mouse by maximal electroshock seizure test",Other,,
1358,768830,1,3,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed BALB/c mouse after 30 mins by rotarod test,Other,,
1359,768832,1,3,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed BALB/c mouse assessed as protection against maximal electroshock-induced seizure after 30 mins,Other,,
1360,810084,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 93/5,Other,,
1361,810085,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 93/5,Other,,
1362,810086,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 93/5,Other,,
1363,810087,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 93/5,Other,,
1364,810088,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 93/5,Other,,
1365,810089,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 93/5,Other,,
1366,810090,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 93/5,Other,,
1367,810091,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 93/5,Other,,
1368,810092,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 93/5,Other,,
1369,810093,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 93/5,Other,,
1370,810094,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 93/5,Other,,
1371,810095,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 93/5,Other,,
1372,810096,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 93/5,Other,,
1373,810097,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 93/5,Other,,
1374,810098,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 93/5,Other,,
1375,810099,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 93/5,Other,,
1376,810100,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 93/5,Other,,
1377,810101,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 93/6,Other,,
1378,810102,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 93/6,Other,,
1379,810103,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 93/6,Other,,
1380,810104,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 93/6,Other,,
1381,810105,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 93/6,Other,,
1382,810106,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 624/13,Other,,
1383,810107,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 624/13,Other,,
1384,810108,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 624/13,Other,,
1385,810109,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 624/13,Other,,
1386,810110,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 624/13,Other,,
1387,810111,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 624/13,Other,,
1388,810112,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 624/14,Other,,
1389,810113,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 624/14,Other,,
1390,810114,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 624/14,Other,,
1391,810142,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 93/14,Other,,
1392,810143,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 93/14,Other,,
1393,810144,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 93/14,Other,,
1394,810145,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 93/14,Other,,
1395,810146,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 93/14,Other,,
1396,810147,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 93/14,Other,,
1397,810148,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 93/14,Other,,
1398,810149,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 93/14,Other,,
1399,810150,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 93/15,Other,,
1400,810151,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 93/15,Other,,
1401,810152,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 93/15,Other,,
1402,810153,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 93/15,Other,,
1403,810154,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 93/15,Other,,
1404,810155,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 93/15,Other,,
1405,810156,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 93/15,Other,,
1406,810157,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 93/15,Other,,
1407,810158,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 93/15,Other,,
1408,810159,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 93/15,Other,,
1409,810474,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 624/14,Other,,
1410,810475,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 624/14,Other,,
1411,810476,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 624/14,Other,,
1412,810477,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 624/14,Other,,
1413,810478,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 624/14,Other,,
1414,810479,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 624/14,Other,,
1415,810480,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 624/14,Other,,
1416,810481,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 624/14,Other,,
1417,810482,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 624/14,Other,,
1418,810483,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 624/14,Other,,
1419,810484,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 624/14,Other,,
1420,810485,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 624/14,Other,,
1421,810486,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 624/14,Other,,
1422,810487,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 624/14,Other,,
1423,810488,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 624/15,Other,,
1424,810489,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 624/15,Other,,
1425,810490,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 624/15,Other,,
1426,810491,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 624/15,Other,,
1427,810492,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 624/15,Other,,
1428,810493,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 624/15,Other,,
1429,810494,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 624/15,Other,,
1430,810495,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 624/15,Other,,
1431,810496,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 624/15,Other,,
1432,810497,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 624/15,Other,,
1433,810498,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 624/15,Other,,
1434,810499,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 624/15,Other,,
1435,810500,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 624/15,Other,,
1436,810501,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 624/15,Other,,
1437,810502,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 624/15,Other,,
1438,810503,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 624/15,Other,,
1439,810504,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 624/15,Other,,
1440,810505,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 624/16,Other,,
1441,810506,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 624/16,Other,,
1442,810507,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 624/16,Other,,
1443,810508,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 624/16,Other,,
1444,810509,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 624/16,Other,,
1445,810510,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 624/16,Other,,
1446,810511,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 624/16,Other,,
1447,810512,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 624/16,Other,,
1448,810519,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 93/15,Other,,
1449,810520,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 93/15,Other,,
1450,810521,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 93/15,Other,,
1451,810522,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 93/15,Other,,
1452,810523,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 93/15,Other,,
1453,810524,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 93/15,Other,,
1454,810525,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 93/15,Other,,
1455,810526,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 93/16,Other,,
1456,810527,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 93/16,Other,,
1457,810528,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 93/16,Other,,
1458,810529,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 93/16,Other,,
1459,810530,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 93/16,Other,,
1460,810531,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 93/16,Other,,
1461,810532,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 93/16,Other,,
1462,810533,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 93/16,Other,,
1463,810534,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 93/16,Other,,
1464,810535,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 93/16,Other,,
1465,810536,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 93/16,Other,,
1466,810537,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 93/16,Other,,
1467,810538,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 93/16,Other,,
1468,810539,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 93/16,Other,,
1469,810540,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 93/16,Other,,
1470,810541,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 93/16,Other,,
1471,810542,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 93/16,Other,,
1472,810543,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 624/5,Other,,
1473,810544,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 624/5,Other,,
1474,810545,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 624/5,Other,,
1475,810546,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 624/5,Other,,
1476,810547,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 624/5,Other,,
1477,811294,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 93/6,Other,,
1478,811636,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 93/6,Other,,
1479,811637,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 93/6,Other,,
1480,811638,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 93/6,Other,,
1481,811639,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 93/6,Other,,
1482,811640,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 93/6,Other,,
1483,811641,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 93/6,Other,,
1484,811642,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 93/6,Other,,
1485,811643,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 93/6,Other,,
1486,811644,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 93/6,Other,,
1487,811645,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 93/6,Other,,
1488,811646,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 93/6,Other,,
1489,811647,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 93/7,Other,,
1490,811648,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 93/7,Other,,
1491,811649,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 93/7,Other,,
1492,811650,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 93/7,Other,,
1493,811651,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 93/7,Other,,
1494,811652,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 93/7,Other,,
1495,811653,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 93/7,Other,,
1496,811654,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 93/7,Other,,
1497,811655,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 93/7,Other,,
1498,811656,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 93/7,Other,,
1499,811657,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 93/7,Other,,
1500,811658,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 93/7,Other,,
1501,811659,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 93/7,Other,,
1502,811660,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 93/7,Other,,
1503,811661,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 93/7,Other,,
1504,811662,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 93/7,Other,,
1505,811663,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 93/7,Other,,
1506,811664,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 93/8,Other,,
1507,811665,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 93/8,Other,,
1508,811666,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 93/8,Other,,
1509,811667,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 93/8,Other,,
1510,811668,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 93/8,Other,,
1511,811669,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 93/8,Other,,
1512,811670,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 93/8,Other,,
1513,811671,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 93/8,Other,,
1514,811672,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 93/8,Other,,
1515,811673,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 93/8,Other,,
1516,811674,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 93/8,Other,,
1517,811675,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 93/8,Other,,
1518,811676,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 93/8,Other,,
1519,811677,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 93/8,Other,,
1520,811678,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 93/8,Other,,
1521,811679,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 93/8,Other,,
1522,811680,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 93/8,Other,,
1523,811717,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 624/5,Other,,
1524,811718,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 624/5,Other,,
1525,811719,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 624/5,Other,,
1526,811720,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 624/5,Other,,
1527,811721,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 624/5,Other,,
1528,811722,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 624/5,Other,,
1529,811723,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 624/5,Other,,
1530,811724,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 624/5,Other,,
1531,811994,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 93/9,Other,,
1532,811995,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 624/16,Other,,
1533,811996,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 624/16,Other,,
1534,811997,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 624/16,Other,,
1535,811998,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 624/16,Other,,
1536,811999,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 624/16,Other,,
1537,812000,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 624/16,Other,,
1538,812001,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 624/16,Other,,
1539,812002,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 624/16,Other,,
1540,812003,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 624/16,Other,,
1541,812040,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 624/5,Other,,
1542,812041,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 624/5,Other,,
1543,812042,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 624/5,Other,,
1544,812043,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 624/5,Other,,
1545,812044,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 624/6,Other,,
1546,812045,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 624/6,Other,,
1547,812046,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 624/6,Other,,
1548,812047,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 624/6,Other,,
1549,812048,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 624/6,Other,,
1550,812049,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 624/6,Other,,
1551,812050,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 624/6,Other,,
1552,812051,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 624/6,Other,,
1553,812052,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 624/6,Other,,
1554,812053,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 624/6,Other,,
1555,812054,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 624/6,Other,,
1556,812055,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 624/6,Other,,
1557,812056,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 624/6,Other,,
1558,812057,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 624/6,Other,,
1559,812058,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 624/6,Other,,
1560,812059,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 624/6,Other,,
1561,812060,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 624/6,Other,,
1562,812061,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 624/7,Other,,
1563,812062,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 624/7,Other,,
1564,812063,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 624/7,Other,,
1565,812064,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 624/7,Other,,
1566,812065,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 624/7,Other,,
1567,812066,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 624/7,Other,,
1568,812067,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 624/7,Other,,
1569,812068,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 624/7,Other,,
1570,812069,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 624/7,Other,,
1571,812070,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 624/7,Other,,
1572,812071,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 624/7,Other,,
1573,812072,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 624/7,Other,,
1574,812073,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 624/7,Other,,
1575,812074,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 624/7,Other,,
1576,812075,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 624/7,Other,,
1577,812076,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 624/7,Other,,
1578,812077,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 624/7,Other,,
1579,812078,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 624/8,Other,,
1580,812079,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 624/8,Other,,
1581,813050,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 624/8,Other,,
1582,813051,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 624/8,Other,,
1583,813052,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 624/8,Other,,
1584,813053,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 624/8,Other,,
1585,813054,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 624/8,Other,,
1586,813055,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 624/8,Other,,
1587,813056,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 624/8,Other,,
1588,813057,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 624/8,Other,,
1589,813058,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 624/8,Other,,
1590,813059,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 624/8,Other,,
1591,813060,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 624/8,Other,,
1592,813061,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 624/8,Other,,
1593,813062,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 624/8,Other,,
1594,813063,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 624/8,Other,,
1595,813064,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 624/8,Other,,
1596,813065,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 624/9,Other,,
1597,813066,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 624/9,Other,,
1598,813067,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 624/9,Other,,
1599,813068,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 624/9,Other,,
1600,813069,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 624/9,Other,,
1601,813070,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 624/9,Other,,
1602,813071,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 624/9,Other,,
1603,813072,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 624/9,Other,,
1604,813073,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 624/9,Other,,
1605,813074,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 624/9,Other,,
1606,813075,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 624/9,Other,,
1607,813076,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 624/9,Other,,
1608,813085,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 93/9,Other,,
1609,813086,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 93/9,Other,,
1610,813087,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 93/9,Other,,
1611,813088,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 93/9,Other,,
1612,813089,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 93/9,Other,,
1613,813090,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 93/9,Other,,
1614,813091,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 93/9,Other,,
1615,813092,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 93/9,Other,,
1616,813093,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 93/9,Other,,
1617,813094,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 93/9,Other,,
1618,813095,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 93/9,Other,,
1619,813096,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 93/9,Other,,
1620,813097,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 93/9,Other,,
1621,813098,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 93/9,Other,,
1622,813099,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 93/9,Other,,
1623,813100,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 93/9,Other,,
1624,813101,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 93/10,Other,,
1625,813102,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 93/10,Other,,
1626,813103,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 93/10,Other,,
1627,813104,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 93/10,Other,,
1628,813105,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 93/10,Other,,
1629,813106,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 93/10,Other,,
1630,813107,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 93/10,Other,,
1631,813108,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 93/10,Other,,
1632,813109,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 93/10,Other,,
1633,813110,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 93/10,Other,,
1634,813111,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 93/10,Other,,
1635,813112,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 93/10,Other,,
1636,813113,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 93/10,Other,,
1637,813114,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 93/10,Other,,
1638,813115,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 93/10,Other,,
1639,813116,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 93/10,Other,,
1640,813117,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 93/10,Other,,
1641,813118,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 93/11,Other,,
1642,813119,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 93/11,Other,,
1643,813120,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 93/11,Other,,
1644,813121,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 93/11,Other,,
1645,813390,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 624/9,Other,,
1646,813391,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 624/9,Other,,
1647,813392,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 624/9,Other,,
1648,813393,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 624/9,Other,,
1649,813394,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 624/9,Other,,
1650,813395,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 624/10,Other,,
1651,813396,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 624/10,Other,,
1652,813397,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 624/10,Other,,
1653,813398,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 624/10,Other,,
1654,813399,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 624/10,Other,,
1655,813400,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 624/10,Other,,
1656,813401,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 624/10,Other,,
1657,813402,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 624/10,Other,,
1658,813403,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 624/10,Other,,
1659,813404,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 624/10,Other,,
1660,813405,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 624/10,Other,,
1661,813406,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 624/10,Other,,
1662,813407,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 624/10,Other,,
1663,813408,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 624/10,Other,,
1664,813409,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 624/10,Other,,
1665,813435,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 93/11,Other,,
1666,813436,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 93/11,Other,,
1667,813437,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 93/11,Other,,
1668,813438,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 93/11,Other,,
1669,813439,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 93/11,Other,,
1670,813440,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 93/11,Other,,
1671,813441,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 93/11,Other,,
1672,813442,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 93/11,Other,,
1673,813443,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 93/11,Other,,
1674,814500,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 624/10,Other,,
1675,814501,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 624/10,Other,,
1676,814502,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 624/11,Other,,
1677,814503,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 624/11,Other,,
1678,814504,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 624/11,Other,,
1679,814505,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 624/11,Other,,
1680,814506,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 624/11,Other,,
1681,814507,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 624/11,Other,,
1682,814508,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 624/11,Other,,
1683,814509,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 624/11,Other,,
1684,814510,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 624/11,Other,,
1685,814511,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 624/11,Other,,
1686,814512,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 624/11,Other,,
1687,814513,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 624/11,Other,,
1688,814514,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 624/11,Other,,
1689,814515,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 624/11,Other,,
1690,814516,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 624/11,Other,,
1691,814517,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 624/11,Other,,
1692,814535,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 93/11,Other,,
1693,814536,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 93/11,Other,,
1694,814537,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 93/11,Other,,
1695,814538,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 93/11,Other,,
1696,814539,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 93/12,Other,,
1697,814540,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 93/12,Other,,
1698,814541,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 93/12,Other,,
1699,814542,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 93/12,Other,,
1700,814543,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 93/12,Other,,
1701,814544,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 93/12,Other,,
1702,814545,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 93/12,Other,,
1703,814546,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 93/12,Other,,
1704,814547,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 93/12,Other,,
1705,814548,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 93/12,Other,,
1706,814549,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 93/12,Other,,
1707,814550,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 93/12,Other,,
1708,814551,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 93/12,Other,,
1709,814552,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 93/12,Other,,
1710,814553,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 93/12,Other,,
1711,814554,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 93/12,Other,,
1712,814555,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 93/12,Other,,
1713,814556,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 93/13,Other,,
1714,814557,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 93/13,Other,,
1715,814558,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 93/13,Other,,
1716,814559,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 93/13,Other,,
1717,814560,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 93/13,Other,,
1718,814561,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 93/13,Other,,
1719,814831,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 624/11,Other,,
1720,814832,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 624/12,Other,,
1721,814833,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 624/12,Other,,
1722,814834,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 624/12,Other,,
1723,814835,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 624/12,Other,,
1724,814836,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 624/12,Other,,
1725,814837,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 624/12,Other,,
1726,814838,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 624/12,Other,,
1727,814839,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 624/12,Other,,
1728,814840,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 624/12,Other,,
1729,814841,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 624/12,Other,,
1730,814842,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 624/12,Other,,
1731,814843,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 624/12,Other,,
1732,814844,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 624/12,Other,,
1733,814845,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 624/12,Other,,
1734,814846,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 624/12,Other,,
1735,814847,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 624/12,Other,,
1736,814848,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 624/12,Other,,
1737,814849,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 624/13,Other,,
1738,814850,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 624/13,Other,,
1739,814851,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 624/13,Other,,
1740,814852,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 624/13,Other,,
1741,814853,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 624/13,Other,,
1742,814854,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 624/13,Other,,
1743,814855,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 624/13,Other,,
1744,814856,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 624/13,Other,,
1745,814857,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 624/13,Other,,
1746,814858,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 624/13,Other,,
1747,814859,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 624/13,Other,,
1748,814876,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 93/13,Other,,
1749,814877,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 93/13,Other,,
1750,814878,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 93/13,Other,,
1751,814879,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 93/13,Other,,
1752,814880,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 93/13,Other,,
1753,814881,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 93/13,Other,,
1754,814882,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 93/13,Other,,
1755,814883,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 93/13,Other,,
1756,814884,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 93/13,Other,,
1757,814885,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 93/13,Other,,
1758,814886,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 93/13,Other,,
1759,814887,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 93/14,Other,,
1760,814888,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 93/14,Other,,
1761,814889,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 93/14,Other,,
1762,814890,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 93/14,Other,,
1763,814891,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 93/14,Other,,
1764,814892,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 93/14,Other,,
1765,814893,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 93/14,Other,,
1766,814894,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 93/14,Other,,
1767,814895,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 93/14,Other,,
1768,872112,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 93/8,Other,,
1769,872113,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 93/8,Other,,
1770,872114,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 93/8,Other,,
1771,872115,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 93/8,Other,,
1772,872116,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 93/8,Other,,
1773,872117,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 93/8,Other,,
1774,872118,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 93/8,Other,,
1775,872119,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 93/8,Other,,
1776,872120,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 93/8,Other,,
1777,872121,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 93/8,Other,,
1778,872122,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 93/8,Other,,
1779,872123,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 93/8,Other,,
1780,872124,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 93/9,Other,,
1781,872125,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 93/9,Other,,
1782,872126,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 93/9,Other,,
1783,872127,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 93/9,Other,,
1784,872128,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 93/9,Other,,
1785,872129,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 93/9,Other,,
1786,872130,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 93/9,Other,,
1787,872131,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 93/9,Other,,
1788,872132,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 93/9,Other,,
1789,872133,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 93/9,Other,,
1790,872134,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 93/9,Other,,
1791,872135,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 93/9,Other,,
1792,872136,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 93/9,Other,,
1793,872137,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 93/9,Other,,
1794,872138,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 93/9,Other,,
1795,872139,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 93/9,Other,,
1796,872140,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 93/9,Other,,
1797,872141,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 93/9,Other,,
1798,872173,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 93/16,Other,,
1799,872174,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 93/16,Other,,
1800,872175,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 93/16,Other,,
1801,872176,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 93/16,Other,,
1802,872177,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 93/16,Other,,
1803,872178,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 93/16,Other,,
1804,872179,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 93/16,Other,,
1805,872180,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 93/16,Other,,
1806,872181,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 93/16,Other,,
1807,872182,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 624/5,Other,,
1808,872183,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 624/5,Other,,
1809,872184,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 624/5,Other,,
1810,872185,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 624/5,Other,,
1811,872186,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 624/5,Other,,
1812,872187,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 624/5,Other,,
1813,872188,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 624/5,Other,,
1814,872189,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 624/5,Other,,
1815,872190,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 624/5,Other,,
1816,872191,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 624/5,Other,,
1817,872192,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 624/5,Other,,
1818,872193,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 624/5,Other,,
1819,872194,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 624/5,Other,,
1820,872195,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 624/5,Other,,
1821,872196,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 624/5,Other,,
1822,872197,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 624/5,Other,,
1823,872198,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 624/5,Other,,
1824,872199,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 624/5,Other,,
1825,872200,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 624/5,Other,,
1826,872201,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 624/5,Other,,
1827,872202,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 624/5,Other,,
1828,872883,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 624/6,Other,,
1829,872884,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 624/6,Other,,
1830,872885,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 624/6,Other,,
1831,872886,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 624/6,Other,,
1832,872887,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 624/6,Other,,
1833,872888,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 624/6,Other,,
1834,872889,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 624/6,Other,,
1835,872890,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 624/6,Other,,
1836,872891,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 624/6,Other,,
1837,872892,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 624/6,Other,,
1838,872893,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 624/6,Other,,
1839,872894,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 624/6,Other,,
1840,872895,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 624/6,Other,,
1841,872896,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 624/6,Other,,
1842,872897,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 624/6,Other,,
1843,872898,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 624/6,Other,,
1844,872899,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 624/6,Other,,
1845,872900,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 624/6,Other,,
1846,872931,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 624/13,Other,,
1847,872932,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 624/13,Other,,
1848,872933,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 624/13,Other,,
1849,872934,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 624/13,Other,,
1850,872935,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 624/13,Other,,
1851,872936,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 624/13,Other,,
1852,872937,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 624/14,Other,,
1853,872938,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 624/14,Other,,
1854,872939,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 624/14,Other,,
1855,872940,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 624/14,Other,,
1856,872941,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 624/14,Other,,
1857,872942,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 624/14,Other,,
1858,872943,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 624/14,Other,,
1859,872944,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 624/14,Other,,
1860,872945,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 624/14,Other,,
1861,872946,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 624/14,Other,,
1862,872947,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 624/14,Other,,
1863,872948,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 624/14,Other,,
1864,872949,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 624/14,Other,,
1865,872950,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 624/14,Other,,
1866,872951,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 624/14,Other,,
1867,872952,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 624/14,Other,,
1868,872953,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 624/14,Other,,
1869,872954,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 624/14,Other,,
1870,872955,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 624/14,Other,,
1871,872956,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 624/14,Other,,
1872,872957,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 624/14,Other,,
1873,872958,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 624/15,Other,,
1874,872959,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 624/15,Other,,
1875,872960,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 624/15,Other,,
1876,872961,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 624/15,Other,,
1877,872962,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 624/15,Other,,
1878,872963,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 624/15,Other,,
1879,872964,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 624/15,Other,,
1880,872965,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 624/15,Other,,
1881,872966,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 624/15,Other,,
1882,872967,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 624/15,Other,,
1883,872968,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 624/15,Other,,
1884,872969,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 624/15,Other,,
1885,872970,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 624/15,Other,,
1886,872971,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 624/15,Other,,
1887,872972,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 624/15,Other,,
1888,872973,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 624/15,Other,,
1889,872974,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 624/15,Other,,
1890,873658,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 624/15,Other,,
1891,873659,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 624/15,Other,,
1892,873660,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 624/15,Other,,
1893,873661,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 624/15,Other,,
1894,874333,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 93/9,Other,,
1895,874334,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 93/9,Other,,
1896,874335,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 93/9,Other,,
1897,874336,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 93/10,Other,,
1898,874337,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 93/10,Other,,
1899,874338,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 93/10,Other,,
1900,874339,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 93/10,Other,,
1901,874340,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 93/10,Other,,
1902,875022,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 93/10,Other,,
1903,875023,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 93/10,Other,,
1904,875024,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 93/10,Other,,
1905,875025,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 93/10,Other,,
1906,875026,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 93/10,Other,,
1907,875027,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 93/10,Other,,
1908,875028,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 93/10,Other,,
1909,875029,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 93/10,Other,,
1910,875030,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 93/10,Other,,
1911,875031,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 93/10,Other,,
1912,875032,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 93/10,Other,,
1913,875033,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 93/10,Other,,
1914,875034,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 93/10,Other,,
1915,875035,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 93/10,Other,,
1916,875036,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 93/10,Other,,
1917,875037,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 93/10,Other,,
1918,875038,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 93/11,Other,,
1919,875039,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 93/11,Other,,
1920,875040,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 93/11,Other,,
1921,875041,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 93/11,Other,,
1922,875042,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 93/11,Other,,
1923,875043,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 93/11,Other,,
1924,875044,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 93/11,Other,,
1925,875045,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 93/11,Other,,
1926,875046,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 93/11,Other,,
1927,875047,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 93/11,Other,,
1928,875048,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 93/11,Other,,
1929,875049,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 93/11,Other,,
1930,875050,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 93/11,Other,,
1931,875051,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 93/11,Other,,
1932,875052,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 93/11,Other,,
1933,875053,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 93/11,Other,,
1934,875054,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 93/11,Other,,
1935,875055,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 93/11,Other,,
1936,875056,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 93/11,Other,,
1937,875057,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 93/11,Other,,
1938,875058,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 93/11,Other,,
1939,875059,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 93/12,Other,,
1940,875060,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 93/12,Other,,
1941,875091,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 624/6,Other,,
1942,875092,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 624/6,Other,,
1943,875093,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 624/6,Other,,
1944,875094,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 624/7,Other,,
1945,875095,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 624/7,Other,,
1946,875096,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 624/7,Other,,
1947,875097,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 624/7,Other,,
1948,875098,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 624/7,Other,,
1949,875099,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 624/7,Other,,
1950,875100,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 624/7,Other,,
1951,875101,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 624/7,Other,,
1952,875102,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 624/7,Other,,
1953,875103,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 624/7,Other,,
1954,875104,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 624/7,Other,,
1955,875105,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 624/7,Other,,
1956,875106,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 624/7,Other,,
1957,875107,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 624/7,Other,,
1958,875108,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 624/7,Other,,
1959,875109,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 624/7,Other,,
1960,875110,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 624/7,Other,,
1961,875111,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 624/7,Other,,
1962,875112,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 624/7,Other,,
1963,875794,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 624/7,Other,,
1964,875795,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 624/7,Other,,
1965,875796,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 624/8,Other,,
1966,875797,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 624/8,Other,,
1967,875798,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 624/8,Other,,
1968,875799,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 624/8,Other,,
1969,875800,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 624/8,Other,,
1970,875801,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 624/8,Other,,
1971,875802,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 624/8,Other,,
1972,875803,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 624/8,Other,,
1973,875804,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 624/8,Other,,
1974,875805,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 624/8,Other,,
1975,875806,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 624/8,Other,,
1976,875807,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 624/8,Other,,
1977,875808,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 624/8,Other,,
1978,875809,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 624/8,Other,,
1979,875810,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 624/8,Other,,
1980,875811,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 624/8,Other,,
1981,875812,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 624/8,Other,,
1982,875813,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 624/8,Other,,
1983,875814,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 624/8,Other,,
1984,875815,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 624/8,Other,,
1985,875816,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 624/8,Other,,
1986,875817,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 624/9,Other,,
1987,875818,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 624/9,Other,,
1988,875819,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 624/9,Other,,
1989,875850,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 624/16,Other,,
1990,875851,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 624/16,Other,,
1991,875852,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 624/16,Other,,
1992,875853,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 624/16,Other,,
1993,875854,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 624/16,Other,,
1994,875855,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 624/16,Other,,
1995,875856,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 624/16,Other,,
1996,875857,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 624/16,Other,,
1997,875858,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 624/16,Other,,
1998,875859,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 624/16,Other,,
1999,875860,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 624/16,Other,,
2000,875861,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 624/16,Other,,
2001,875862,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 624/16,Other,,
2002,875863,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 624/16,Other,,
2003,875864,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 624/16,Other,,
2004,875865,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 624/16,Other,,
2005,875866,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 624/16,Other,,
2006,875867,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 624/16,Other,,
2007,875868,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 624/16,Other,,
2008,875869,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 624/16,Other,,
2009,875870,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 624/16,Other,,
2010,877891,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 93/5,Other,,
2011,877892,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 93/5,Other,,
2012,877893,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 93/5,Other,,
2013,877894,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 93/5,Other,,
2014,877895,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 93/5,Other,,
2015,877896,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 93/5,Other,,
2016,877897,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 93/5,Other,,
2017,877898,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 93/5,Other,,
2018,877931,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 93/12,Other,,
2019,877932,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 93/12,Other,,
2020,877933,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 93/12,Other,,
2021,877934,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 93/12,Other,,
2022,877935,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 93/12,Other,,
2023,877936,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 93/12,Other,,
2024,877937,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 93/12,Other,,
2025,877938,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 93/12,Other,,
2026,877939,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 93/12,Other,,
2027,877940,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 93/12,Other,,
2028,877941,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 93/12,Other,,
2029,877942,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 93/12,Other,,
2030,877943,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 93/12,Other,,
2031,877944,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 93/12,Other,,
2032,877945,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 93/12,Other,,
2033,877946,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 93/12,Other,,
2034,877947,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 93/12,Other,,
2035,877948,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 93/12,Other,,
2036,877949,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 93/12,Other,,
2037,877950,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 93/13,Other,,
2038,877951,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 93/13,Other,,
2039,877952,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 93/13,Other,,
2040,877953,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 93/13,Other,,
2041,877954,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 93/13,Other,,
2042,877955,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 93/13,Other,,
2043,877956,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 93/13,Other,,
2044,877957,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 93/13,Other,,
2045,877958,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 93/13,Other,,
2046,877959,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 93/13,Other,,
2047,877960,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 93/13,Other,,
2048,877961,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 93/13,Other,,
2049,877962,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 93/13,Other,,
2050,877963,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 93/13,Other,,
2051,877964,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 93/13,Other,,
2052,877965,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 93/13,Other,,
2053,877966,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 93/13,Other,,
2054,877967,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 93/13,Other,,
2055,877968,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 93/13,Other,,
2056,877969,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 93/13,Other,,
2057,877970,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 93/13,Other,,
2058,877971,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 93/14,Other,,
2059,877972,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 93/14,Other,,
2060,877973,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 93/14,Other,,
2061,877974,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 93/14,Other,,
2062,877975,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 93/14,Other,,
2063,878008,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 624/9,Other,,
2064,878009,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 624/9,Other,,
2065,878010,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 624/9,Other,,
2066,878011,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 624/9,Other,,
2067,878012,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 624/9,Other,,
2068,878013,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 624/9,Other,,
2069,878014,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 624/9,Other,,
2070,878015,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 624/9,Other,,
2071,878016,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 624/9,Other,,
2072,878017,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 624/9,Other,,
2073,878018,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 624/9,Other,,
2074,878019,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 624/9,Other,,
2075,878020,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 624/9,Other,,
2076,878021,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 624/9,Other,,
2077,878659,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 93/14,Other,,
2078,878660,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 93/14,Other,,
2079,878704,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 624/9,Other,,
2080,878705,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 624/9,Other,,
2081,878706,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 624/9,Other,,
2082,878707,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 624/9,Other,,
2083,878708,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 624/10,Other,,
2084,878709,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 624/10,Other,,
2085,878710,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 624/10,Other,,
2086,878711,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 624/10,Other,,
2087,878712,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 624/10,Other,,
2088,878713,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 624/10,Other,,
2089,878714,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 624/10,Other,,
2090,878715,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 624/10,Other,,
2091,878716,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 624/10,Other,,
2092,878717,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 624/10,Other,,
2093,878718,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 624/10,Other,,
2094,878719,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 624/10,Other,,
2095,878720,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 624/10,Other,,
2096,878721,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 624/10,Other,,
2097,878722,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 624/10,Other,,
2098,878723,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 624/10,Other,,
2099,878724,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 624/10,Other,,
2100,878725,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 624/10,Other,,
2101,878726,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 624/10,Other,,
2102,878727,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 624/10,Other,,
2103,878728,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 624/10,Other,,
2104,878729,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 624/11,Other,,
2105,878730,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 624/11,Other,,
2106,878731,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 624/11,Other,,
2107,878732,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 624/11,Other,,
2108,878733,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 624/11,Other,,
2109,878734,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 624/11,Other,,
2110,878735,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 624/11,Other,,
2111,878736,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 624/11,Other,,
2112,878737,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 624/11,Other,,
2113,880092,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 93/5,Other,,
2114,880093,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 93/5,Other,,
2115,880094,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 93/5,Other,,
2116,880095,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 93/5,Other,,
2117,880096,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 93/5,Other,,
2118,880097,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 93/5,Other,,
2119,880098,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 93/5,Other,,
2120,880099,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 93/5,Other,,
2121,880100,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 93/5,Other,,
2122,880101,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 93/5,Other,,
2123,880102,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 93/5,Other,,
2124,880103,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 93/5,Other,,
2125,880104,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 93/5,Other,,
2126,880105,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 93/6,Other,,
2127,880106,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 93/6,Other,,
2128,880107,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 93/6,Other,,
2129,880108,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 93/6,Other,,
2130,880109,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 93/6,Other,,
2131,880110,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 93/6,Other,,
2132,880111,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 93/6,Other,,
2133,880112,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 93/6,Other,,
2134,880113,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 93/6,Other,,
2135,880114,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 93/6,Other,,
2136,880115,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 93/6,Other,,
2137,880116,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 93/6,Other,,
2138,880796,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 93/6,Other,,
2139,880797,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 93/6,Other,,
2140,880798,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 93/6,Other,,
2141,880799,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 93/6,Other,,
2142,880800,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 93/6,Other,,
2143,880801,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 93/6,Other,,
2144,880802,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 93/6,Other,,
2145,880803,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 93/6,Other,,
2146,880804,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 93/6,Other,,
2147,880805,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 93/7,Other,,
2148,880806,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 93/7,Other,,
2149,880807,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 93/7,Other,,
2150,880808,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 93/7,Other,,
2151,880809,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 93/7,Other,,
2152,880810,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 93/7,Other,,
2153,880811,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 93/7,Other,,
2154,880812,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 93/7,Other,,
2155,880813,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 93/7,Other,,
2156,880814,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 93/7,Other,,
2157,880815,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 93/7,Other,,
2158,880816,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 93/7,Other,,
2159,880817,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 93/7,Other,,
2160,880849,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 93/14,Other,,
2161,880850,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 93/14,Other,,
2162,880851,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 93/14,Other,,
2163,880852,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 93/14,Other,,
2164,880853,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 93/14,Other,,
2165,880854,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 93/14,Other,,
2166,880855,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 93/14,Other,,
2167,880856,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 93/14,Other,,
2168,880857,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 93/14,Other,,
2169,880858,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 93/14,Other,,
2170,880859,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 93/14,Other,,
2171,880860,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 93/14,Other,,
2172,880861,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 93/14,Other,,
2173,880862,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 93/14,Other,,
2174,880863,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 93/15,Other,,
2175,880864,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 93/15,Other,,
2176,880865,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 93/15,Other,,
2177,880866,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 93/15,Other,,
2178,880867,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 93/15,Other,,
2179,880868,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 93/15,Other,,
2180,880869,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 93/15,Other,,
2181,880870,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 93/15,Other,,
2182,880871,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 93/15,Other,,
2183,880872,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 93/15,Other,,
2184,880873,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 93/15,Other,,
2185,880874,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 93/15,Other,,
2186,880875,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 93/15,Other,,
2187,880876,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 93/15,Other,,
2188,880877,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 93/15,Other,,
2189,880878,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 93/15,Other,,
2190,880879,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 93/15,Other,,
2191,880880,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 93/15,Other,,
2192,880881,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 93/15,Other,,
2193,880882,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 93/15,Other,,
2194,880883,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 93/15,Other,,
2195,880884,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 93/16,Other,,
2196,880885,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 93/16,Other,,
2197,880926,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 624/11,Other,,
2198,880927,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 624/11,Other,,
2199,880928,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 624/11,Other,,
2200,880929,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 624/11,Other,,
2201,880930,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 624/11,Other,,
2202,880931,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 624/11,Other,,
2203,881571,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 93/16,Other,,
2204,881572,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 93/16,Other,,
2205,881573,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 93/16,Other,,
2206,881574,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 93/16,Other,,
2207,881575,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 93/16,Other,,
2208,881576,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 93/16,Other,,
2209,881577,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 93/16,Other,,
2210,881578,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 93/16,Other,,
2211,881579,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 93/16,Other,,
2212,881580,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 93/16,Other,,
2213,881616,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 624/11,Other,,
2214,881617,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 624/11,Other,,
2215,881618,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 624/11,Other,,
2216,881619,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 624/11,Other,,
2217,881620,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 624/11,Other,,
2218,881621,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 624/11,Other,,
2219,881622,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 624/12,Other,,
2220,881623,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 624/12,Other,,
2221,881624,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 624/12,Other,,
2222,881625,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 624/12,Other,,
2223,881626,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 624/12,Other,,
2224,881627,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 624/12,Other,,
2225,881628,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 624/12,Other,,
2226,881629,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 624/12,Other,,
2227,881630,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 624/12,Other,,
2228,881631,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 624/12,Other,,
2229,881632,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 624/12,Other,,
2230,881633,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 624/12,Other,,
2231,881634,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 624/12,Other,,
2232,881635,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 624/12,Other,,
2233,881636,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 624/12,Other,,
2234,881637,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 624/12,Other,,
2235,881638,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 624/12,Other,,
2236,881639,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 624/12,Other,,
2237,881640,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 624/12,Other,,
2238,881641,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 624/12,Other,,
2239,881642,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 624/12,Other,,
2240,881643,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 624/13,Other,,
2241,881644,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 624/13,Other,,
2242,881645,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 624/13,Other,,
2243,881646,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 624/13,Other,,
2244,881647,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 624/13,Other,,
2245,881648,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 624/13,Other,,
2246,881649,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 624/13,Other,,
2247,881650,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 624/13,Other,,
2248,881651,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 624/13,Other,,
2249,881652,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 624/13,Other,,
2250,881653,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 624/13,Other,,
2251,881654,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 624/13,Other,,
2252,881655,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 624/13,Other,,
2253,881656,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 624/13,Other,,
2254,881657,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 624/13,Other,,
2255,883012,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 93/7,Other,,
2256,883013,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 93/7,Other,,
2257,883014,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 93/7,Other,,
2258,883015,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 93/7,Other,,
2259,883016,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 93/7,Other,,
2260,883017,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 93/7,Other,,
2261,883018,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 93/7,Other,,
2262,883019,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 93/7,Other,,
2263,883020,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 93/8,Other,,
2264,883021,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 93/8,Other,,
2265,883022,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 93/8,Other,,
2266,883023,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 93/8,Other,,
2267,883024,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 93/8,Other,,
2268,883025,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 93/8,Other,,
2269,883026,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 93/8,Other,,
2270,883027,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 93/8,Other,,
2271,883028,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 93/8,Other,,
2272,929344,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R030916,Other,,
2273,929345,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R030916,Other,,
2274,929346,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R030916,Other,,
2275,929347,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R030916,Other,,
2276,929348,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R030916,Other,,
2277,929349,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R030916,Other,,
2278,929350,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R030916,Other,,
2279,929351,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R030916,Other,,
2280,929352,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R030916,Other,,
2281,929353,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R030916,Other,,
2282,929354,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R030916,Other,,
2283,929355,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R030916,Other,,
2284,929356,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R030916,Other,,
2285,946591,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020115,Other,,
2286,946592,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020115,Other,,
2287,946593,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020115,Other,,
2288,946594,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020115,Other,,
2289,946595,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020115,Other,,
2290,946596,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020115,Other,,
2291,946597,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020115,Other,,
2292,946598,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020115,Other,,
2293,946599,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020115",Other,,
2294,946600,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020115,Other,,
2295,946601,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020115,Other,,
2296,946602,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020115,Other,,
2297,946603,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020115,Other,,
2298,946604,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020115,Other,,
2299,946605,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020115,Other,,
2300,946606,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020115,Other,,
2301,946607,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020115,Other,,
2302,946608,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020115,Other,,
2303,946609,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020115,Other,,
2304,948616,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R030916,Other,,
2305,948617,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R030916,Other,,
2306,948618,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R030916,Other,,
2307,948619,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R030916,Other,,
2308,948620,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R030916,Other,,
2309,948621,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R030916,Other,,
2310,948622,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R030916,Other,,
2311,948623,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R030916,Other,,
2312,948624,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R030916,Other,,
2313,948625,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R030916,Other,,
2314,948626,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R030916,Other,,
2315,948627,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R030916,Other,,
2316,948628,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R030916,Other,,
2317,948629,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020115,Other,,
2318,948630,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020115",Other,,
2319,948631,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020115,Other,,
2320,949141,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020115,Other,,
2321,949142,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020115,Other,,
2322,949143,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020115,Other,,
2323,949144,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020115,Other,,
2324,949145,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020115,Other,,
2325,949272,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020115,Other,,
2326,949273,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020115,Other,,
2327,949274,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020115,Other,,
2328,949275,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020115,Other,,
2329,949276,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020115,Other,,
2330,949277,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020115,Other,,
2331,949278,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020115,Other,,
2332,949279,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020115,Other,,
2333,949280,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020115,Other,,
2334,949281,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020115,Other,,
2335,949282,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020115,Other,,
2336,953501,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R030916,Other,,
2337,953502,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R030916,Other,,
2338,953503,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R030916,Other,,
2339,953504,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R030916,Other,,
2340,953505,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R030916,Other,,
2341,953506,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R030916,Other,,
2342,953507,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R030916,Other,,
2343,953508,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R030916,Other,,
2344,953509,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R030916,Other,,
2345,953510,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R030916,Other,,
2346,953511,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R030916,Other,,
2347,953512,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R030916,Other,,
2348,953513,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R030916,Other,,
2349,953514,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R030916,Other,,
2350,954147,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R030916,Other,,
2351,954148,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020115,Other,,
2352,954149,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020115,Other,,
2353,954150,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020115,Other,,
2354,954151,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020115,Other,,
2355,954152,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020115,Other,,
2356,954153,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020115,Other,,
2357,954154,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020115,Other,,
2358,954155,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020115,Other,,
2359,954156,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020115,Other,,
2360,954157,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020115,Other,,
2361,954158,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020115,Other,,
2362,954159,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020115,Other,,
2363,954160,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020115,Other,,
2364,954161,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020115,Other,,
2365,954162,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020115,Other,,
2366,954163,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020115,Other,,
2367,954164,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020115,Other,,
2368,954165,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020115,Other,,
2369,954166,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020115,Other,,
2370,962911,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020115,Other,,
2371,962912,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020115,Other,,
2372,962913,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020115,Other,,
2373,962914,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020115,Other,,
2374,962915,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020115,Other,,
2375,962916,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020115,Other,,
2376,962917,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020115,Other,,
2377,962918,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020115,Other,,
2378,962919,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020115,Other,,
2379,962920,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020115,Other,,
2380,962921,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020115,Other,,
2381,963300,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020115,Other,,
2382,963301,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020115,Other,,
2383,963302,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020115,Other,,
2384,963303,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020115,Other,,
2385,963304,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020115,Other,,
2386,963305,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020115,Other,,
2387,963306,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020115,Other,,
2388,963307,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020115,Other,,
2389,968387,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R030916,Other,,
2390,968388,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R030916,Other,,
2391,968389,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R030916,Other,,
2392,968390,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R030916,Other,,
2393,968391,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R030916,Other,,
2394,968392,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R030916,Other,,
2395,968393,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R030916,Other,,
2396,968394,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R030916,Other,,
2397,971047,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R030916,Other,,
2398,971048,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R030916,Other,,
2399,971049,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R030916,Other,,
2400,971050,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R030916,Other,,
2401,971051,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R030916,Other,,
2402,971052,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R030916,Other,,
2403,971053,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R030916,Other,,
2404,985937,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030916",Other,,
2405,985938,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: R030916",Other,,
2406,985939,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: R030916",Other,,
2407,985940,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: R030916",Other,,
2408,985941,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R030916",Other,,
2409,986523,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: R030916",Other,,
2410,986524,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: R030916",Other,,
2411,986525,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: R030916",Other,,
2412,986526,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: R030916,Other,,
2413,986527,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: R030916",Other,,
2414,986528,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: R030916",Other,,
2415,986529,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: R030916",Other,,
2416,986530,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: R030916,Other,,
2417,986531,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: R030916",Other,,
2418,986532,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: R030916",Other,,
2419,986533,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: R030916",Other,,
2420,986534,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: R030916",Other,,
2421,986535,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: R030916",Other,,
2422,986536,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: R030916",Other,,
2423,993337,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R030916",Other,,
2424,993338,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: R030916",Other,,
2425,993339,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: R030916",Other,,
2426,993340,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: R030916",Other,,
2427,993341,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: R030916",Other,,
2428,993342,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: R030916",Other,,
2429,993343,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: R030916,Other,,
2430,993344,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: R030916",Other,,
2431,993345,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: R030916,Other,,
2432,993346,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: R030916",Other,,
2433,993929,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: R030916",Other,,
2434,993930,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: R030916",Other,,
2435,993931,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: R030916",Other,,
2436,993932,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: R030916",Other,,
2437,993933,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: R030916",Other,,
2438,993934,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: R030916",Other,,
2439,993935,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: R030916",Other,,
2440,993936,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030916",Other,,
2441,993937,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030916",Other,,
2442,993938,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: R030916",Other,,
2443,993939,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: R030916",Other,,
2444,993940,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: R030916",Other,,
2445,993941,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: R030916",Other,,
2446,993942,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: R030916",Other,,
2447,993943,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: R030916",Other,,
2448,993944,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: R030916",Other,,
2449,993945,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: R030916",Other,,
2450,993946,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: R030916",Other,,
2451,993947,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: R030916",Other,,
2452,993948,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: R030916,Other,,
2453,993949,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: R030916,Other,,
2454,993950,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: R030916",Other,,
2455,993951,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: R030916",Other,,
2456,993952,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: R030916",Other,,
2457,993953,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: R030916,Other,,
2458,993954,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: R030916",Other,,
2459,993955,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: R030916",Other,,
2460,993956,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: R030916",Other,,
2461,993957,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: R030916",Other,,
2462,993958,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: R030916,Other,,
2463,1006521,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020115",Other,,
2464,1006522,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020115,Other,,
2465,1006523,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2466,1006524,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020115",Other,,
2467,1006525,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020115",Other,,
2468,1006526,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2469,1006527,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020115",Other,,
2470,1006528,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020115",Other,,
2471,1006529,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020115",Other,,
2472,1006530,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020115,Other,,
2473,1006531,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020115",Other,,
2474,1006532,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020115",Other,,
2475,1006533,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020115",Other,,
2476,1006534,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020115,Other,,
2477,1006535,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2478,1006536,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020115",Other,,
2479,1006537,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2480,1006538,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2481,1006539,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020115",Other,,
2482,1013924,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020115",Other,,
2483,1013925,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2484,1013926,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020115",Other,,
2485,1013927,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020115",Other,,
2486,1013928,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020115",Other,,
2487,1013929,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2488,1013930,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020115",Other,,
2489,1013931,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020115,Other,,
2490,1013932,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020115",Other,,
2491,1013933,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020115,Other,,
2492,1013934,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020115",Other,,
2493,1013935,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020115",Other,,
2494,1013936,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020115",Other,,
2495,1013937,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020115",Other,,
2496,1013938,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2497,1013939,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2498,1013940,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020115",Other,,
2499,1013941,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020115",Other,,
2500,1013942,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2501,1013943,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020115",Other,,
2502,1013944,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2503,1013945,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2504,1013946,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020115",Other,,
2505,1013947,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2506,1013948,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2507,1013949,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2508,1013950,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020115",Other,,
2509,1013951,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2510,1013952,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2511,1013953,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020115",Other,,
2512,1013954,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2513,1013955,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020115,Other,,
2514,1013956,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020115,Other,,
2515,1013957,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020115",Other,,
2516,1013958,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2517,1013959,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020115",Other,,
2518,1013960,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020115,Other,,
2519,1014542,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2520,1014543,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2521,1014544,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2522,1015631,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020115",Other,,
2523,1015632,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020115",Other,,
2524,1015633,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020115",Other,,
2525,1015634,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2526,1015635,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020115,Other,,
2527,1015636,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020115",Other,,
2528,1015637,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020115,Other,,
2529,1015638,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020115",Other,,
2530,1015639,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020115",Other,,
2531,1015640,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020115",Other,,
2532,1015641,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020115",Other,,
2533,1015642,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2534,1015643,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2535,1017511,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020115",Other,,
2536,1017512,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020115",Other,,
2537,1017513,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020115",Other,,
2538,1017514,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2539,1017515,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2540,1017516,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020115",Other,,
2541,1017517,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2542,1017518,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2543,1017519,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2544,1017520,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020115",Other,,
2545,1017521,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2546,1017522,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2547,1017523,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020115",Other,,
2548,1017524,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2549,1017525,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020115,Other,,
2550,1017526,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020115,Other,,
2551,1017527,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020115",Other,,
2552,1017528,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2553,1017529,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2554,1017530,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020115",Other,,
2555,1017531,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020115,Other,,
2556,1017532,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2557,1017533,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2558,1017534,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2559,1018119,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020115",Other,,
2560,1018120,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020115,Other,,
2561,1018121,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2562,1018122,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020115",Other,,
2563,1018123,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020115",Other,,
2564,1018124,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2565,1018125,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020115",Other,,
2566,1018126,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020115",Other,,
2567,1018127,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020115",Other,,
2568,1018128,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020115",Other,,
2569,1018129,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020115,Other,,
2570,1018130,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020115",Other,,
2571,1018131,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020115",Other,,
2572,1018132,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020115",Other,,
2573,1018133,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020115,Other,,
2574,1018134,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2575,1018135,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020115",Other,,
2576,1020006,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2577,1020007,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2578,1020008,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2579,1020009,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020115",Other,,
2580,1024953,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020115",Other,,
2581,1026190,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020115,Other,,
2582,1026191,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020115,Other,,
2583,1026192,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020115",Other,,
2584,1026193,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2585,1026194,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2586,1026195,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020115",Other,,
2587,1026196,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020115,Other,,
2588,1026197,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2589,1026198,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2590,1026199,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2591,1026200,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020115",Other,,
2592,1026201,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020115,Other,,
2593,1026202,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2594,1026203,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020115",Other,,
2595,1026204,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020115",Other,,
2596,1026205,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2597,1026206,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020115",Other,,
2598,1026207,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020115",Other,,
2599,1026208,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020115",Other,,
2600,1026209,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020115,Other,,
2601,1026210,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020115",Other,,
2602,1026211,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020115",Other,,
2603,1026212,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020115,Other,,
2604,1026213,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2605,1026214,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020115",Other,,
2606,1026215,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2607,1026216,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2608,1026217,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2609,1026218,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020115",Other,,
2610,1028637,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020115",Other,,
2611,1028638,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020115",Other,,
2612,1028639,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020115",Other,,
2613,1028640,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020115",Other,,
2614,1028641,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2615,1028642,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020115",Other,,
2616,1028643,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020115",Other,,
2617,1028644,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020115,Other,,
2618,1028645,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020115",Other,,
2619,1028646,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020115,Other,,
2620,1028647,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020115",Other,,
2621,1028648,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020115",Other,,
2622,1028649,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020115",Other,,
2623,1028650,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020115",Other,,
2624,1028651,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2625,1028652,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020115",Other,,
2626,1028653,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2627,1028654,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020115",Other,,
2628,1028655,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020115",Other,,
2629,1028656,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2630,1028657,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2631,1028658,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020115",Other,,
2632,1028659,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2633,1028660,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2634,1028661,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2635,1028662,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020115",Other,,
2636,1028663,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2637,1028664,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2638,1028665,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020115",Other,,
2639,1028666,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2640,1029067,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2641,1029068,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020115",Other,,
2642,1029069,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2643,1029070,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020115",Other,,
2644,1029071,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020115",Other,,
2645,1029072,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020115",Other,,
2646,1029073,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2647,1029074,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020115",Other,,
2648,1029075,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2649,1029076,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020115",Other,,
2650,1029077,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020115",Other,,
2651,1029078,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020115",Other,,
2652,1029079,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020115,Other,,
2653,1029080,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020115",Other,,
2654,1029081,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020115,Other,,
2655,1029082,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020115",Other,,
2656,1029083,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020115",Other,,
2657,1029084,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020115",Other,,
2658,1029085,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020115",Other,,
2659,1030954,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020115",Other,,
2660,1030955,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2661,1030956,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2662,1030957,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2663,1030958,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020115",Other,,
2664,1030959,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2665,1030960,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2666,1030961,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2667,1030962,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020115",Other,,
2668,1030963,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2669,1030964,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020115",Other,,
2670,1030965,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2671,1031550,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020115",Other,,
2672,1031551,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020115,Other,,
2673,1031552,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020115,Other,,
2674,1031553,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020115",Other,,
2675,1031554,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020115",Other,,
2676,1031555,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020115,Other,,
2677,1031556,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2678,1031557,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020115",Other,,
2679,1031558,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020115,Other,,
2680,1031559,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020115",Other,,
2681,1031560,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2682,1031561,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2683,1031562,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020115",Other,,
2684,1031563,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020115",Other,,
2685,1031564,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020115",Other,,
2686,1031565,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020115",Other,,
2687,1031566,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020115",Other,,
2688,1031567,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020115",Other,,
2689,1031568,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020115",Other,,
2690,1031569,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020115",Other,,
2691,1031570,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020115",Other,,
2692,1031571,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020115,Other,,
2693,1031572,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2694,1031573,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020115",Other,,
2695,1031574,1,3,,103165722,4763,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020115,Other,,
2696,1031575,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2697,1031576,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020115",Other,,
2698,1031577,1,3,,103165722,4763,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 0.25 day; Dose: Low; Vehicle: 100 % water; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020115",Other,,
2699,1049642,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 93/12,Other,,
2700,1049643,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 93/12,Other,,
2701,1049644,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 93/13,Other,,
2702,1049645,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 93/13,Other,,
2703,1049646,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 93/13,Other,,
2704,1049647,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 93/13,Other,,
2705,1049648,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 93/13,Other,,
2706,1049649,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 93/14,Other,,
2707,1049650,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 93/14,Other,,
2708,1049651,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 93/14,Other,,
2709,1049652,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 93/14,Other,,
2710,1049653,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 93/14,Other,,
2711,1049654,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 93/15,Other,,
2712,1049655,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 93/15,Other,,
2713,1049656,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 93/15,Other,,
2714,1049657,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 93/15,Other,,
2715,1049658,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 93/15,Other,,
2716,1049659,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 93/16,Other,,
2717,1049660,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 93/16,Other,,
2718,1049661,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 93/16,Other,,
2719,1049662,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 93/16,Other,,
2720,1049663,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 93/16,Other,,
2721,1049664,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 624/5,Other,,
2722,1049665,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 624/5,Other,,
2723,1049666,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 624/5,Other,,
2724,1049667,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 624/5,Other,,
2725,1049668,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 624/5,Other,,
2726,1049669,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 624/6,Other,,
2727,1049670,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 624/6,Other,,
2728,1049671,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 624/6,Other,,
2729,1049672,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 624/6,Other,,
2730,1049673,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 624/6,Other,,
2731,1049674,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 624/7,Other,,
2732,1049675,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 624/7,Other,,
2733,1049676,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 624/7,Other,,
2734,1049677,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 624/7,Other,,
2735,1049678,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 624/7,Other,,
2736,1049679,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 624/8,Other,,
2737,1049680,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 624/8,Other,,
2738,1049681,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 624/8,Other,,
2739,1049682,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 624/8,Other,,
2740,1049939,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 624/8,Other,,
2741,1049940,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 624/9,Other,,
2742,1049941,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 624/9,Other,,
2743,1049942,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 624/9,Other,,
2744,1049943,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 624/9,Other,,
2745,1049944,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 624/9,Other,,
2746,1050677,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 624/10,Other,,
2747,1050678,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 624/10,Other,,
2748,1050679,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 624/10,Other,,
2749,1050680,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 624/10,Other,,
2750,1050681,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 624/10,Other,,
2751,1050682,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 624/11,Other,,
2752,1050683,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 624/11,Other,,
2753,1050684,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 624/11,Other,,
2754,1050685,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 624/11,Other,,
2755,1050686,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 624/11,Other,,
2756,1050687,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 624/12,Other,,
2757,1050688,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 624/12,Other,,
2758,1050689,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 624/12,Other,,
2759,1050690,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 624/12,Other,,
2760,1050691,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 624/12,Other,,
2761,1050692,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 624/13,Other,,
2762,1050693,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 624/13,Other,,
2763,1050694,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 624/13,Other,,
2764,1050695,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 624/13,Other,,
2765,1050696,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 624/13,Other,,
2766,1050697,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 624/14,Other,,
2767,1050698,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 624/14,Other,,
2768,1050699,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 624/14,Other,,
2769,1050700,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 624/14,Other,,
2770,1050701,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 624/14,Other,,
2771,1050702,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 624/15,Other,,
2772,1050703,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 624/15,Other,,
2773,1050704,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 624/15,Other,,
2774,1050705,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 624/15,Other,,
2775,1050706,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 624/15,Other,,
2776,1050707,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 624/16,Other,,
2777,1050708,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 624/16,Other,,
2778,1050709,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 624/16,Other,,
2779,1050923,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 624/16,Other,,
2780,1050924,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 624/16,Other,,
2781,1052698,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 93/5,Other,,
2782,1052699,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 93/5,Other,,
2783,1052700,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 93/5,Other,,
2784,1052701,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 93/5,Other,,
2785,1052702,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 93/5,Other,,
2786,1052703,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 93/6,Other,,
2787,1052704,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 93/6,Other,,
2788,1052705,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 93/6,Other,,
2789,1052706,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 93/6,Other,,
2790,1052707,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 93/6,Other,,
2791,1052708,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 93/7,Other,,
2792,1052709,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 93/7,Other,,
2793,1052710,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 93/7,Other,,
2794,1052711,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 93/7,Other,,
2795,1052712,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 93/7,Other,,
2796,1052713,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 93/8,Other,,
2797,1052714,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 93/8,Other,,
2798,1052715,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 93/8,Other,,
2799,1052716,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 93/8,Other,,
2800,1052717,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 93/8,Other,,
2801,1052718,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 93/9,Other,,
2802,1052719,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 93/9,Other,,
2803,1052720,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 93/9,Other,,
2804,1052721,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 93/9,Other,,
2805,1052722,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 93/9,Other,,
2806,1052723,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 93/10,Other,,
2807,1052724,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 93/10,Other,,
2808,1052725,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 93/10,Other,,
2809,1052726,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 93/10,Other,,
2810,1052727,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 93/10,Other,,
2811,1052728,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 93/11,Other,,
2812,1052729,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 93/11,Other,,
2813,1052730,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 93/11,Other,,
2814,1052731,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 93/11,Other,,
2815,1052732,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 93/11,Other,,
2816,1052733,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 93/12,Other,,
2817,1052734,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 93/12,Other,,
2818,1052735,1,2,,103165722,4763,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 93/12,Other,,
2819,1053175,2,1,,124813340,4763,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
2820,1053197,1,1,,51087546,4763,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
2821,1079931,1,1,,103165722,4763,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
2822,1079932,1,1,,103165722,4763,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
2823,1079933,1,1,,103165722,4763,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
2824,1079934,1,1,,103165722,4763,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
2825,1079935,1,1,,103165722,4763,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
2826,1079936,1,1,,103165722,4763,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
2827,1079937,1,1,,103165722,4763,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
2828,1079938,1,1,,103165722,4763,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
2829,1079939,1,1,,103165722,4763,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
2830,1079940,1,1,,103165722,4763,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
2831,1079941,1,1,,103165722,4763,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
2832,1079942,1,1,,103165722,4763,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
2833,1079943,1,1,,103165722,4763,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
2834,1079944,1,1,,103165722,4763,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
2835,1079945,1,1,,103165722,4763,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
2836,1079946,1,1,,103165722,4763,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
2837,1079947,1,1,,103165722,4763,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
2838,1079948,1,1,,103165722,4763,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
2839,1079949,1,1,,103165722,4763,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
2840,1083364,1,2,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for Mus musculus albino (mouse) to ED50 for Mus musculus albino (mouse) by maximal electroshock-induced seizures test",Other,,
2841,1083365,1,2,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for Mus musculus albino (mouse) to ED50 for Mus musculus albino (mouse) by subcutaneous pentylenetetrazol-induced seizures test",Other,,
2842,1083366,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus albino (mouse) assessed as protection against subcutaneous pentylenetetrazol-induced seizures,Other,,
2843,1083367,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus albino (mouse) assessed as protection against maximal electroshock-induced seizures,Other,,
2844,1083368,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Mus musculus albino (mouse) after 4 hr rotorod test,Other,,
2845,1083369,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Mus musculus albino (mouse) after 0.5 hr rotorod test,Other,,
2846,1083370,1,2,,103165722,4763,Inactive,,,,,"Anticonvulsant activity in Mus musculus albino (mouse) assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 300 mg/kg, ip after 4 hr",Other,,
2847,1083371,1,2,,103165722,4763,Inactive,,,,,"Anticonvulsant activity in Mus musculus albino (mouse) assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 300 mg/kg, ip after 0.5 hr",Other,,
2848,1083376,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus albino (mouse) assessed as protection against maximal electroshock-induced seizures after 4 hr,Other,,
2849,1083377,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus albino (mouse) assessed as protection against maximal electroshock-induced seizures after 0.5 hr,Other,,
2850,1083853,2,1,,103165722,4763,Unspecified,,,,,"Lipophilicity, log P of the compound",Other,,
2851,1083854,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus (mouse) assessed as protection against pentylenetetrazole-induced seizures administered 1 hr before pentylenetetrazole challenge measured after 30 min,Other,,
2852,1083855,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Mus musculus (mouse) assessed as protection against pentylenetetrazole-induced seizures at 20 mg/kg, ip administered 1 hr before pentylenetetrazole challenge measured after 30 min",Other,,
2853,1083858,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Mus musculus (mouse) assessed as protection against pentylenetetrazole-induced seizures at 15 mg/kg, ip administered 1 hr before pentylenetetrazole challenge measured after 30 min",Other,,
2854,1083861,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Mus musculus (mouse) assessed as protection against pentylenetetrazole-induced seizures at 10 mg/kg, ip administered 1 hr before pentylenetetrazole challenge measured after 30 min",Other,,
2855,1084573,1,2,,103165722,4763,Unspecified,,,,,"Sedative-hypnotic activity in Mus musculus (mouse) assessed as increase in duration of phenobarbital-induced sleep at 19.6 to 42.6 mg/kg, ip incubated for 30 min prior to phenobarbital challenge relative to phenobarbital-treated mouse",Other,,
2856,1084574,1,2,,103165722,4763,Unspecified,,,,,"Sedative-hypnotic activity in Mus musculus (mouse) assessed as decrease in onset of phenobarbital-induced sleep at 19.6 to 42.6 mg/kg, ip incubated for 30 min prior to phenobarbital challenge relative to phenobarbital-treated mouse",Other,,
2857,1085323,1,2,,103165722,4763,Unspecified,,,,,"Neurotoxicity in Mus musculus Swiss albino (mouse) assessed as motor impairment at 600 mg/kg, ip measured for 1 min by rotarod test",Other,,
2858,1085324,1,2,,103165722,4763,Unspecified,,,,,"Neurotoxicity in Mus musculus Swiss albino (mouse) assessed as motor impairment at 100 mg/kg, ip measured for 1 min by rotarod test",Other,,
2859,1085330,1,2,,103165722,4763,Active,,,,,"Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against subcutaneous pentylenetetrazol-induced clonic spasms at 30 mg/kg, ip after 4 hr post compound treatment",Other,,
2860,1085331,1,2,,103165722,4763,Active,,,,,"Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against subcutaneous pentylenetetrazol-induced clonic spasms at 30 mg/kg, ip after 0.5 hr post compound treatment",Other,,
2861,1085576,1,2,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for Mus musculus Swiss (mouse) to ED50 for Mus musculus Swiss (mouse) by subcutaneous pentylenetetrazole-induced seizure test",Other,,
2862,1085577,1,2,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for Mus musculus Swiss (mouse) to ED50 for Mus musculus Swiss (mouse) by maximal electroshock-induced seizure test",Other,,
2863,1085578,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Mus musculus Swiss (mouse) assessed as minimum motor impairment by rotarod test,Other,,
2864,1085579,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity against subcutaneous pentylenetetrazole-induced seizures in ip dosed Mus musculus Swiss (mouse) at 30 mg/kg, ip measured at phase 2",Other,,
2865,1085580,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity against maximal electroshock-induced seizures in ip dosed Mus musculus Swiss (mouse) administered 30 min before MES induction measured at phase 2,Other,,
2866,1087067,1,2,,103165722,4763,Unspecified,,,,,"Neurotoxicity in Mus musculus albino (mouse) assessed as minimal motor impairment at 15 mg/kg, ip measured for 180 secs by rotorod test",Other,,
2867,1087070,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in pentylenetetrazole-induced Mus musculus albino (mouse) seizure model assessed as death time at 15 mg/kg, ip administered 30 min followed by pentylenetetrazole induction measured for 30 min (Rvb = 416 +/- 58.2 secs)",Other,,
2868,1087075,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in pentylenetetrazole-induced Mus musculus albino (mouse) seizure model assessed as survival at 15 mg/kg, ip administered 30 min followed by pentylenetetrazole induction measured for 30 min relative to control",Other,,
2869,1087080,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Mus musculus albino (mouse) assessed as protection against pentylenetetrazole-induced seizure at 15 mg/kg, ip administered 30 min followed by pentylenetetrazole induction measured for 30 min relative to control",Other,,
2870,1087085,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Mus musculus albino (mouse) assessed as decrease in pentylenetetrazole-induced total seizure time at 15 mg/kg, ip administered 30 min followed by pentylenetetrazole induction measured for 30 min (Rvb = 9.9 +/- 1.3 secs)",Other,,
2871,1087090,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Mus musculus albino (mouse) assessed as increase in onset of pentylenetetrazole-induced seizure at 15 mg/kg, ip administered 30 min followed by pentylenetetrazole induction measured for 30 min (Rvb = 184 +/- 32 secs)",Other,,
2872,1095651,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Mus musculus (mouse) after 4 hr by rotorod test,Other,,
2873,1095652,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed Mus musculus (mouse) after 0.5 hr by rotorod test,Other,,
2874,1095657,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus (mouse) assessed as protection against subcutaneous pentyleneterazole-induced seizure measured after 4 hr,Other,,
2875,1095658,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus (mouse) assessed as protection against subcutaneous pentyleneterazole-induced seizure measured after 0.5 hr,Other,,
2876,1095659,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus (mouse) assessed as protection against maximal electroshock-induced seizure measured after 4 hr,Other,,
2877,1095660,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus (mouse) assessed as protection against maximal electroshock-induced seizure measured after 0.5 hr,Other,,
2878,1096158,1,2,,103165722,4763,Unspecified,,,,,"Toxicity in Mus musculus albino (mouse) assessed as mortality at 160 to 400 mg/kg, ip after 24 hr",Other,,
2879,1096159,1,2,,103165722,4763,Unspecified,,,,,"Toxicity in Mus musculus albino (mouse) assessed as mortality at 100 mg/kg, ip after 24 hr",Other,,
2880,1096162,1,2,,103165722,4763,Unspecified,,,,,Toxicity in ip dosed Mus musculus albino (mouse) after 24 hr,Other,,
2881,1096164,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr,Other,,
2882,1096165,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures at 30 mg/kg, ip administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr relative to control",Other,,
2883,1096166,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures at 20 mg/kg, ip administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr relative to control",Other,,
2884,1096167,1,2,,103165722,4763,Unspecified,,,,,"Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizures at 10 mg/kg, ip administered 1 hr prior to pentylenetetrazole-challenge measured up to 1 hr relative to control",Other,,
2885,1096199,1,2,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity to ED50 for anticonvulsant activity in mouse",Other,,
2886,1096200,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity against ip dosed Mus musculus (mouse) by rotarod test,Other,,
2887,1096201,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus (mouse) assessed as protection against maximal electroshock-induced seizures administered 30 min prior to electroshock-challenge measured at 4 hr,Other,,
2888,1096247,1,2,,103165722,4763,Unspecified,,,,,"Protection index, ratio TD50 for neurotoxicity to ED50 for protection against maximal electroshock-induced seizure in Mus musculus Swiss albino (mouse)",Other,,
2889,1096248,1,2,,103165722,4763,Unspecified,,,,,Neurotoxicity against ip dosed Mus musculus Swiss albino (mouse) by rota rod test,Other,,
2890,1096249,1,2,,103165722,4763,Inactive,,,,,"Anticonvulsant activity in Mus musculus Swiss albino (mouse) assessed as protection against against strychnine-induced seizure at 300 mg/kg, ip",Other,,
2891,1096252,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus Swiss albino (mouse) assessed as protection against pentylenetetrazole-induced seizure,Other,,
2892,1096254,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus Swiss albino (mouse) assessed as protection against maximal electroshock-induced seizure,Other,,
2893,1096724,1,2,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for ip dosed Mus musculus (mouse) to ED50 for ip dosed Mus musculus (mouse) assessed as inhibition of maximal electroshock-induced seizure",Other,,
2894,1096725,1,2,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for po dosed Rattus norvegicus (rat) to ED50 for anticonvulsant activity in po dosed rat assessed as inhibition of maximal electroshock-induced seizure",Other,,
2895,1096730,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed Rattus norvegicus (rat) assessed as inhibition of maximal electroshock-induced seizure after 5 hr,Other,,
2896,1096736,1,2,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed Mus musculus (mouse) assessed as inhibition of maximal electroshock-induced seizure after 1 hr,Other,,
2897,1116946,1,2,,103165722,4763,Unspecified,,,,,"Neurotoxicity in albino Mus musculus (mouse) assessed as motor impairment at 30 mg/kg, sc after 4 hr relative to control",Other,,
2898,1116950,1,2,,103165722,4763,Unspecified,,,,,"Neurotoxicity in albino Mus musculus (mouse) assessed as motor impairment at 30 mg/kg, sc after 0.5 hr relative to control",Other,,
2899,1116954,1,2,,103165722,4763,Active,,,,,"Anticonvulsant activity in albino Mus musculus (mouse) assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 30 mg/kg, sc after 4 hr relative to control",Other,,
2900,1116958,1,2,,103165722,4763,Active,,,,,"Anticonvulsant activity in albino Mus musculus (mouse) assessed as protection against subcutaneous pentylenetetrazol-induced seizures at 30 mg/kg, sc after 0.5 hr relative to control",Other,,
2901,1116962,1,2,,103165722,4763,Active,,,,,"Anticonvulsant activity in albino Mus musculus (mouse) assessed as protection against maximal electroshock-induced seizures at 30 mg/kg, sc after 4 hr relative to control",Other,,
2902,1116966,1,2,,103165722,4763,Active,,,,,"Anticonvulsant activity in albino Mus musculus (mouse) assessed as protection against maximal electroshock-induced seizures at 30 mg/kg, sc after 0.5 hr relative to control",Other,,
2903,1117267,1,1,,51087546,4763,Inactive,48145933.0,7276.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of Transthyretin (TTR) transcription,Screening,,
2904,1123418,1,1,,103165722,4763,Unspecified,,,,,Induction of muscle relaxation/sedation in po dosed mouse by inclined screen test,Other,34039.0,
2905,1123419,1,1,,103165722,4763,Unspecified,,,,,Induction of taming effect in po dosed mouse by foot shock method,Other,34039.0,
2906,1123420,1,1,,103165722,4763,Unspecified,,,,,Muscle relaxing activity in po dosed cat,Other,34039.0,
2907,1123421,1,1,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as reduction of pentylenetetrazole-induced seizures,Other,34039.0,
2908,1123422,1,1,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as reduction of maximal electroshock-induced seizures,Other,34039.0,
2909,1123423,1,1,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed mouse assessed as reduction of minimal electroshock-induced seizures,Other,34039.0,
2910,1130940,1,1,,103165722,4763,Unspecified,,,,,Retention index of the compound by HPLC method,Other,533876.0,
2911,1130943,2,1,,103165722,4763,Unspecified,,,,,"Octanol-water partition coefficient, log P of nonionized form of compound",Other,533876.0,
2912,1130944,1,1,,103165722,4763,Unspecified,,,,,Hypnotic activity in rabbit,Other,533876.0,
2913,1130945,1,1,,103165722,4763,Unspecified,,,,,Inhibition of Arbacia egg cell division,Other,533876.0,
2914,1136302,1,1,,103165722,4763,Unspecified,,,,,Ratio of LD50 for po dosed mouse to PD50 for acute toxicity in po dosed mouse assessed as concentration required to produce 50% loss of righting reflex,Other,31473.0,
2915,1139131,1,1,,103165722,4763,Unspecified,,,,,"Toxicity in Swiss mouse assessed as time spent on rotating rod at 40 mg/kg, po administered 1 hr prior to testing (Rvb = 119 +/- 1 secs)",Other,24685703.0,
2916,1145372,1,1,,103165722,4763,Unspecified,,,,,Induction of hypnotic activity in rabbit,Other,1271398.0,
2917,1146455,1,1,,103165722,4763,Unspecified,,,,,Neuroleptic activity in ip dosed mouse assessed as blockade of righting reflex by measuring failure to right to normal position measured for 30 secs,Other,29124.0,
2918,1146456,1,1,,103165722,4763,Unspecified,,,,,Neuroleptic activity in ip dosed mouse assessed as blockade of traction reflex by measuring failure to grasp wire with hind paws measured for 5 secs,Other,29124.0,
2919,1146457,1,1,,103165722,4763,Unspecified,,,,,Neuroleptic activity in ip dosed mouse assessed as blockade of prehensile reflex by measuring failure to hang measured for 5 secs,Other,29124.0,
2920,1146458,1,2,,103165722,4763,Unspecified,,,,,Neuroleptic activity in ip dosed mouse assessed as blockade of corneal reflex by measuring failure to blink,Other,29124.0,
2921,1159387,1,2,,103165722,4763,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
2922,1159509,1,1,,144207708,4763,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2923,1159515,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2924,1159516,1,1,,144207708,4763,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2925,1159517,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2926,1159518,1,1,,144207708,4763,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2927,1159519,1,1,,144207708,4763,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2928,1159520,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2929,1159521,1,1,,144207708,4763,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2930,1159523,1,1,,144207708,4763,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2931,1159524,1,1,,51087546,4763,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2932,1159525,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2933,1159526,1,1,,144207708,4763,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2934,1159527,1,1,,144207708,4763,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2935,1159528,1,1,,144207708,4763,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2936,1159529,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2937,1159531,1,1,,144207708,4763,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2938,1159551,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2939,1159552,1,1,,144207708,4763,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2940,1159553,2,1,,144207708,4763,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2941,1159555,1,1,,144207708,4763,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2942,1159606,1,1,,51087546,4763,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
2943,1159620,1,1,,103165722,4763,Active,,,,,Summary of drug indications.,Other,,
2944,1161059,1,1,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizures,Other,25150088.0,
2945,1161060,1,1,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against subcutaneous metrazol-induced seizures,Other,25150088.0,
2946,1161061,1,1,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed albino CF1 mouse,Other,25150088.0,
2947,1161062,1,1,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in ip dosed albino CF1 mouse to ED50 for anticonvulsant activity in ip dosed MES albino CF1 mouse model",Other,25150088.0,
2948,1161063,1,1,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino CF1 mouse assessed as protection against maximal electroshock-induced seizures measured as time to peak effect,Other,25150088.0,
2949,1162021,1,1,,103165722,4763,Unspecified,,,,,Toxicity in Zebrafish embryo assessed as induction of changes in body shape at 3000 uM,Other,25171781.0,
2950,1162022,1,1,,103165722,4763,Unspecified,,,,,Toxicity in Zebrafish embryo assessed as induction of changes in somites at 3000 uM,Other,25171781.0,
2951,1162023,1,1,,103165722,4763,Unspecified,,,,,Toxicity in Zebrafish embryo assessed as induction of changes in notochords at 3000 uM,Other,25171781.0,
2952,1162024,1,1,,103165722,4763,Unspecified,,,,,Toxicity in Zebrafish embryo assessed as induction of changes in tail region at 3000 uM,Other,25171781.0,
2953,1162025,1,1,,103165722,4763,Unspecified,,,,,Toxicity in Zebrafish embryo assessed as induction of changes in fins region at 3000 uM,Other,25171781.0,
2954,1162026,1,1,,103165722,4763,Unspecified,,,,,Toxicity in Zebrafish embryo assessed as induction of changes in brain region at 3000 uM,Other,25171781.0,
2955,1162027,1,1,,103165722,4763,Unspecified,,,,,Toxicity in Zebrafish embryo assessed as induction of changes in upper jaw region at 3000 uM,Other,25171781.0,
2956,1162028,1,1,,103165722,4763,Unspecified,,,,,Toxicity in Zebrafish embryo assessed as induction of changes in heart region at 3000 uM,Other,25171781.0,
2957,1162029,1,2,,103165722,4763,Unspecified,,,,,Toxicity in Zebrafish embryo assessed as induction of changes in intestine region at 3000 uM,Other,25171781.0,
2958,1162030,1,1,,103165722,4763,Unspecified,,,,,Toxicity in Zebrafish embryo assessed as induction of changes in lower jaw region at 3000 uM,Other,25171781.0,
2959,1162031,1,2,,103165722,4763,Unspecified,,,,,Toxicity in Zebrafish embryo assessed as induction of changes in liver region at 3000 uM,Other,25171781.0,
2960,1162032,1,1,,103165722,4763,Unspecified,,,,,Toxicity in Zebrafish embryo assessed as induction of changes in swim bladder region at 3000 uM,Other,25171781.0,
2961,1191614,1,1,,103165722,4763,Active,,,,,"Anticonvulsant activity in Swiss albino mouse model of pentylenetetrazole-induced kindling related chronic epilepsy assessed as reduction in incidence and seizure severity score by at 30 mg/kg, ip administered daily for 5 weeks followed by injection of 30 mg/kg, ip PTZ on every alternate day till full kindling development",Other,25619635.0,
2962,1191617,1,2,,103165722,4763,Active,,,,,"Reduction in MDA level in brain of Swiss albino mouse model of pentylenetetrazole-induced kindling related chronic epilepsy at 30 mg/kg, ip administered daily for 5 weeks followed by injection of 30 mg/kg, ip PTZ on every alternate day till full kindling development by spectrophotometry",Other,25619635.0,
2963,1191620,1,2,,103165722,4763,Inactive,,,,,"Increase in GSH level in brain of Swiss albino mouse model of pentylenetetrazole-induced kindling related chronic epilepsy at 30 mg/kg, ip administered daily for 5 weeks followed by injection of 30 mg/kg, ip PTZ on every alternate day till full kindling development by Ellman's reagent based assay",Other,25619635.0,
2964,1191621,1,2,,103165722,4763,Inactive,,,,,"Increase in GSH-Px level in brain of Swiss albino mouse model of pentylenetetrazole-induced kindling related chronic epilepsy at 30 mg/kg, ip administered daily for 5 weeks followed by injection of 30 mg/kg, ip PTZ on every alternate day till full kindling development",Other,25619635.0,
2965,1191623,1,2,,103165722,4763,Inactive,,,,,"Reduction in nitric oxide level in brain of Swiss albino mouse model of pentylenetetrazole-induced kindling related chronic epilepsy at 30 mg/kg, ip administered daily for 5 weeks followed by injection of 30 mg/kg, ip PTZ on every alternate day till full kindling development by Griess reagent based assay",Other,25619635.0,
2966,1211702,1,2,,103165722,4763,Active,49066046.0,9970.0,,,Transactivation of human CAR1 transfected in human primary hepatocytes assessed as nuclear translocation at 1 mM by confocal laser scanning microscopy,Other,23439660.0,
2967,1213967,1,2,,103165722,4763,Unspecified,117205.0,1555.0,,,Induction of CYP2B6 in human hepatocytes using bupropion as substrate at 0.3 to 30 uM treated every 24 hrs for 2 days measured on day 5 by LC-MS/MS analysis relative to control,Other,22930276.0,
2968,1224834,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2969,1224835,1,1,,144207708,4763,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2970,1224836,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2971,1224837,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2972,1224838,1,1,,144207708,4763,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2973,1224839,1,1,,144207708,4763,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2974,1224840,3,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2975,1224841,3,1,,144207708,4763,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2976,1224842,3,1,,144207708,4763,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2977,1224843,1,1,,144207708,4763,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2978,1224844,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
2979,1224845,1,1,,144207708,4763,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
2980,1224846,1,1,,144207708,4763,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
2981,1224847,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
2982,1224848,3,1,,144207708,4763,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2983,1224849,3,1,,144207708,4763,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2984,1224865,1,2,,51087546,4763,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
2985,1224867,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
2986,1224868,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
2987,1224869,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
2988,1224870,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
2989,1224871,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
2990,1224872,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
2991,1224873,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
2992,1224874,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
2993,1224875,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
2994,1224876,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
2995,1224877,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
2996,1224878,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
2997,1224879,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
2998,1224880,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
2999,1224881,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3000,1224882,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3001,1224883,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3002,1224884,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3003,1224885,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3004,1224886,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3005,1224887,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3006,1224888,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3007,1224889,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3008,1224890,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3009,1224892,1,1,,144207708,4763,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3010,1224893,1,1,,144207708,4763,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3011,1224894,1,1,,144207708,4763,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3012,1224895,1,1,,144207708,4763,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3013,1224896,1,1,,144207708,4763,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3014,1232846,1,1,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in ip dosed albino Carworth Farms No. 1 mouse measured at 1 hr by maximal electroshock seizure test,Other,25922183.0,
3015,1232851,1,1,,103165722,4763,Unspecified,,,,,Neurotoxicity in ip dosed albino Carworth Farms No. 1 mouse measured at 0.5 hrs by rotarod test,Other,25922183.0,
3016,1232854,1,1,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for neurotoxicity in ip dosed albino Carworth Farms No. 1 mouse to ED50 for anticonvulsant activity in ip dosed MES albino Carworth Farms No. 1 mouse model",Other,25922183.0,
3017,1232861,1,1,,103165722,4763,Unspecified,,,,,Anticonvulsant activity in po dosed albino Sprague-Dawley rat measured at 5 hrs by maximal electroshock seizure test,Other,25922183.0,
3018,1232864,1,1,,103165722,4763,Unspecified,,,,,Behavioural toxicity in po dosed albino Sprague-Dawley rat measured at 0.5 hrs,Other,25922183.0,
3019,1232867,1,1,,103165722,4763,Unspecified,,,,,"Protective index, ratio of TD50 for behavioural toxicity in po dosed albino Sprague-Dawley rat to ED50 for anticonvulsant activity in po dosed MES albino Sprague-Dawley rat model",Other,25922183.0,
3020,1259241,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3021,1259242,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3022,1259243,1,1,,144207708,4763,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3023,1259244,1,1,,144207708,4763,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3024,1259247,1,1,,144207708,4763,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3025,1259248,1,1,,144207708,4763,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3026,1259309,1,1,,124813340,4763,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3027,1259310,1,1,,321942509,4763,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
3028,1259311,1,1,,124813340,4763,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3029,1259313,1,1,,51087546,4763,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3030,1259318,1,1,,51087546,4763,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3031,1259344,1,1,,144205266,4763,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
3032,1259355,1,1,,144205266,4763,Inconclusive,,,0.7943,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
3033,1259356,1,1,,144205266,4763,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
3034,1259364,1,1,,144207708,4763,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3035,1259365,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3036,1259366,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3037,1259367,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3038,1259368,1,1,,144207708,4763,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3039,1259369,1,1,,144207708,4763,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3040,1259377,1,1,,144207708,4763,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3041,1259378,1,1,,144207708,4763,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3042,1259379,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3043,1259380,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3044,1259381,1,1,,144207708,4763,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3045,1259382,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3046,1259383,1,1,,144207708,4763,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3047,1259384,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3048,1259385,1,1,,144207708,4763,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3049,1259386,1,1,,144207708,4763,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3050,1259387,1,1,,144207708,4763,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3051,1259388,1,1,,144207708,4763,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3052,1259390,1,1,,144207708,4763,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3053,1259391,1,1,,144207708,4763,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3054,1259392,1,1,,144207708,4763,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3055,1259393,1,1,,144207708,4763,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3056,1259394,1,1,,144207708,4763,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3057,1259395,1,1,,144207708,4763,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3058,1259396,1,1,,144207708,4763,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3059,1259401,1,1,,144207708,4763,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3060,1259402,1,1,,144207708,4763,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3061,1259403,1,1,,144207708,4763,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3062,1259404,1,1,,144207708,4763,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3063,1259407,1,1,,363898452,4763,Inactive,,,,,CCRIS mutagenicity studies,Other,,
3064,1259408,1,1,,363894749,4763,Inactive,,,,,GENE-TOX mutagenicity studies,Other,,
3065,1259409,1,1,,363898452,4763,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
3066,1259410,1,1,,363898452,4763,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
3067,1259411,1,1,,363898452,4763,Active,,,,,CCRIS carcinogenicity studies,Other,,
3068,1259415,1,1,,51087546,4763,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
